proach
recent
studi
immunomodul
paracrin
effect
adult
stem
progenitor
cell
notabl
adult
mesenchym
stromal
stem
cell
msc
deriv
bone
marrow
adipos
tissu
increasingli
provid
evid
efficaci
anim
model
acut
fibrot
lung
injuri
well
asthma
bronchopulmonari
dysplasia
chronic
obstruct
pulmonari
diseas
copd
sepsi
lung
diseas
although
mechan
msc
effect
model
yet
fulli
understood
grow
evid
implic
solubl
mediat
releas
msc
well
cell
cell
contact
msc
differ
inflammatori
immun
effector
cell
studi
recent
extend
human
lung
explant
model
anticip
clinic
investig
initi
safeti
efficaci
msc
acut
lung
injuri
occur
near
futur
parallel
interim
analysi
current
clinic
trial
unit
state
assess
system
administr
msc
patient
moder
sever
copd
demonstr
safeti
yield
promis
result
respect
efficaci
trial
complet
observ
period
data
expect
releas
late
earli
circul
endotheli
progenitor
cell
epc
contribut
regener
diseas
pulmonari
vasculatur
two
recent
clinic
investig
china
suggest
efficaci
autolog
bone
marrowderiv
epc
administr
adult
pediatr
patient
pulmonari
hypertens
compar
trial
autolog
epc
administr
pulmonari
hypertens
pulmonari
hypertens
assess
cell
therapi
phacet
trial
ongo
canada
circul
endotheli
progenitor
cell
may
also
play
role
acut
lung
injuri
fibrot
lung
diseas
engraft
system
intratrach
administ
cell
remain
controversi
issu
although
avail
evid
argu
signific
engraft
public
abstract
present
confer
suggest
sever
newli
investig
cell
type
includ
deriv
placent
tissu
novel
cell
popul
deriv
adult
bone
marrow
may
demonstr
robust
abil
engraft
particip
lung
repair
signific
advanc
continu
made
novel
area
investig
includ
increas
explor
cultur
system
bioengin
approach
gener
function
lung
tissu
ex
vivo
vivo
culmin
first
success
clinic
use
bioengin
trachea
parallel
sever
recent
report
demonstr
potenti
feasibl
use
decellular
whole
lung
scaffold
recellular
subsequ
implant
area
predict
intens
investig
next
sever
year
compar
progress
continu
studi
embryon
stem
cell
esc
induc
pluripot
stem
cell
ip
sever
group
present
protocol
deriv
definit
endoderm
either
esc
ip
cultur
vitro
demonstr
abil
gener
cell
phenotyp
marker
type
alveolar
cell
either
mous
human
esc
addit
recent
studi
demonstr
potenti
abil
type
alveolar
epitheli
cell
deriv
cultur
human
embryon
stem
cell
engraft
lung
amelior
experiment
induc
lung
injuri
rodent
model
nonetheless
mani
challeng
remain
gener
function
lung
cell
either
esc
ip
one
potenti
fruit
area
investig
deriv
recent
demonstr
gener
diseasespecif
ip
tissu
sampl
obtain
patient
cystic
fibrosi
antitrypsin
defici
genet
acquir
lung
diseas
signific
progress
continu
made
investig
local
endogen
stem
progenitor
cell
resid
lung
advanc
lineagetrac
approach
techniqu
provid
import
insight
understand
ident
lineag
expans
properti
previous
identifi
put
endogen
progenitor
popul
suggest
increasingli
complex
network
cellular
repair
injuri
howev
studi
endogen
lung
stem
progenitor
cell
remain
complic
role
specif
microenvironment
nich
cell
resid
alter
nich
experiment
protocol
remov
cell
nich
chang
identifi
characterist
biolog
activ
one
challeng
continu
face
field
continu
devis
refin
lineag
trace
studi
mechan
defin
character
explor
potenti
therapeut
andor
patholog
properti
endogen
lung
progenitor
cell
includ
studi
lung
cancer
stem
cell
area
increas
focu
high
interest
remain
incomplet
understood
anoth
challeng
studi
endogen
progenitor
cell
continu
use
mous
model
correl
inform
human
lung
remain
poorli
defin
continu
issu
confus
terminolog
despit
suggest
guidelin
previou
confer
sourc
precis
definit
character
specif
cell
popul
notabl
put
endogen
cell
popul
lung
well
mesenchym
stromal
cell
endotheli
progenitor
cell
agre
upon
term
stem
cell
progenitor
cell
still
use
vari
degre
clariti
precis
differ
investig
recent
public
continu
complic
comparison
differ
investig
approach
glossari
relev
work
definit
applic
lung
origin
present
report
confer
depict
tabl
glossari
necessarili
reflect
consensu
definit
term
undergo
continu
revis
overal
understand
cell
type
mechan
involv
lung
repair
continu
elucid
nonetheless
use
framework
first
session
endogen
lung
progenitor
cellslung
cancer
stem
cell
follow
overview
field
paul
simmon
univers
texa
respect
present
susan
reynold
nation
jewish
ed
morrisey
univers
pennsylvania
barri
stripp
duke
majd
moud
univers
pittsburgh
kerstin
sinkeviciu
boston
children
hospit
review
current
state
knowledg
endogen
progenitor
cell
popul
mechan
regul
behavior
potenti
initi
augment
repair
includ
lesson
learn
lung
develop
role
local
microenvironment
nich
consider
lung
cancer
progenitor
cell
key
point
emphas
session
stem
cell
oper
defin
sole
intrins
development
potenti
interact
microenviron
resid
stem
cell
nich
dynam
tempor
nich
capac
modifi
stem
cell
behaviorreadout
differ
context
moreov
stem
cellassoci
marker
uniqu
express
stem
cell
unreli
predictor
stem
progenitor
cell
potenti
isol
cell
valid
function
assay
lineagetrac
studi
particularli
interrog
isol
cell
histomorphometr
spatial
posit
cue
lost
increasingli
valid
necessari
second
session
embryon
stem
cell
ip
lung
regener
includ
featur
talk
nuclear
reprogram
pluripot
konrad
hochedling
massachusett
gener
follow
present
carolyn
lutzko
lo
angel
children
hospit
darrel
kotton
boston
univers
rick
wetsel
univers
texa
peter
lelk
drexel
univers
highlight
develop
area
one
notabl
advanc
area
improv
sophist
direct
esc
vitro
stage
involv
gener
definit
endoderm
subsequ
cell
phenotyp
characterist
type
alveolar
epitheli
cell
compar
data
demonstr
ip
similarli
manipul
toward
definit
endoderm
potenti
toward
lung
epitheli
cell
howev
full
phenotyp
function
character
put
lung
cell
deriv
esc
ip
remain
controversi
also
area
rigor
method
requir
novel
data
present
demonstr
first
time
vivo
administr
escderiv
cell
could
mitig
experiment
induc
lung
injuri
whether
reflect
engraft
cell
lung
heretofor
unrecogn
paracrin
effect
yet
clear
third
session
bioengin
approach
lung
regener
featur
overview
dame
julia
polak
imperi
final
session
summat
direct
featur
review
current
state
lung
engraft
dian
kraus
yale
follow
perspect
given
repres
nhlbi
fda
sponsor
nonprofit
respiratori
diseas
organ
present
ethic
polici
issu
stem
cell
research
jeffrey
kahn
univers
minnesota
summari
david
scadden
harvard
stem
cell
institut
confer
conclud
vigor
discuss
futur
research
fund
prioriti
led
darwin
prockop
texa
previou
confer
discuss
spirit
proceed
clinic
investig
addit
recent
trial
copd
pulmonari
hypertens
agre
strong
emphasi
must
continu
place
anim
model
human
lung
diseas
focu
studi
incorpor
relev
function
outcom
measur
nonetheless
safeti
initi
efficaci
result
obtain
trial
msc
copd
abil
singl
cell
divid
produc
differenti
cell
organ
includ
extraembryon
tissu
thu
gener
organ
total
mammal
zygot
first
cleavag
blastomer
totipot
pluripot
abil
singl
cell
produc
differenti
cell
type
repres
three
germ
layer
thu
form
lineag
matur
organ
exampl
embryon
stem
cell
abil
adult
stem
cell
form
multipl
cell
type
one
lineag
exampl
hematopoiet
stem
cell
unipot
cell
form
one
cell
type
exampl
spermatogoni
stem
cell
gener
sperm
reprogram
chang
epigenet
lead
increas
potenc
dedifferenti
induc
nuclear
transfer
cell
fusion
genet
manipul
transdifferenti
capac
differenti
somat
cell
acquir
phenotyp
differenti
cell
differ
lineag
exampl
epithelialmesenchym
transit
emt
process
wherebi
fulli
differenti
epitheli
cell
undergo
transit
mesenchym
phenotyp
give
rise
fibroblast
myofibroblast
plastic
hypothesi
somat
stem
cell
broaden
potenc
gener
cell
lineag
concept
controversi
mammal
embryon
stem
cell
cell
isol
inner
mass
earli
develop
blastocyst
es
cell
capac
self
renew
pluripot
abil
differenti
cell
embryolog
lineag
adult
cell
type
howev
es
cell
form
extraembryon
tissu
trophectoderm
adult
stem
cell
cell
isol
adult
tissu
includ
bone
marrow
adipos
tissu
nervou
tissu
skin
umbil
cord
blood
placenta
capac
self
renew
gener
adult
stem
cell
multipot
capac
differenti
matur
cell
type
parent
tissu
popul
adult
stem
cell
msc
exhibit
rang
lineag
differenti
limit
singl
tissu
type
whether
adult
stem
cell
exhibit
plastic
differenti
wider
varieti
differenti
cell
tissu
remain
controversi
adult
tissuespecif
stem
cell
adult
stem
cell
defin
tissu
specif
rel
undifferenti
cell
within
given
tissu
capac
selfrenew
stabl
mainten
within
stem
cell
nich
adult
tissuespecif
endogen
stem
cell
differenti
potenti
equival
cellular
divers
tissu
resid
hematopoiet
stem
cell
prototyp
adult
tissu
stem
cell
induc
pluripot
stem
cell
reprogram
adult
somat
cell
undergon
dedifferenti
dermal
fibroblast
reprogram
retrovir
transduct
express
four
transcript
factor
oct
cmyc
ip
cell
similar
es
cell
morpholog
prolifer
gene
express
abil
form
teratoma
vivo
implant
ip
cell
result
format
tissu
three
embryon
germ
layer
ip
cell
gener
mous
human
cell
progenitor
cell
collect
term
use
describ
prolif
cell
capac
differenti
differ
cell
lineag
within
given
tissu
unlik
stem
cell
progenitor
cell
limit
selfrenew
capac
term
progenitor
cell
commonli
use
indic
cell
expand
rapidli
undergo
senesc
multipl
cell
doubl
terminolog
take
account
function
distinct
among
progenitor
cell
suggest
transitamplifi
cell
progeni
endogen
tissu
stem
cell
retain
rel
undifferenti
charact
although
differenti
parent
stem
cell
finit
capac
prolifer
sole
function
transitamplifi
cell
gener
suffici
number
special
progeni
tissu
mainten
oblig
progenitor
cell
cell
lose
abil
prolifer
commit
differenti
pathway
intestin
transitamplifi
cell
oblig
progenitor
cell
facult
progenitor
cell
cell
exhibit
differenti
featur
quiescent
state
yet
capac
prolifer
normal
tissu
mainten
respons
injuri
bronchiolar
clara
cell
exampl
cell
type
classic
stem
cell
hierarchi
stem
cell
hierarchi
adult
tissu
stem
cell
activ
particip
normal
tissu
mainten
give
rise
transitamplifi
cell
within
type
hierarchi
renew
potenti
resid
cell
top
hierarchi
stem
transitamplifi
cell
cell
success
stage
prolifer
becom
progress
differenti
nonclass
stem
cell
hierarchi
stem
cell
hierarchi
adult
tissu
stem
cell
typic
particip
normal
tissu
mainten
activ
particip
repair
follow
progenitor
cell
deplet
rapidli
renew
tissu
tissu
homeostasi
depend
mainten
activ
mitot
compart
rapid
turnov
differenti
cell
type
requir
continu
prolifer
stem
andor
transitamplifi
cell
prototyp
rapidli
renew
tissu
intestin
epithelium
slowli
renew
tissu
tissu
steadyst
mitot
index
low
special
cell
type
broadli
distribut
longliv
subset
cell
facult
progenitor
cell
retain
abil
enter
cell
cycl
rel
stabil
differenti
cell
pool
parallel
infrequ
prolifer
stem
andor
transit
amplifi
cell
lung
exampl
slowli
renew
tissu
hematopoiet
stem
cell
cell
capac
self
renew
abil
differenti
matur
leukocyt
erythrocyt
platelet
whether
hsc
exhibit
plastic
differenti
matur
cell
lineag
remain
controversi
endotheli
progenitor
cell
circul
cell
potenti
prolifer
differenti
matur
endotheli
cell
studi
epc
complic
use
terminolog
defin
least
two
differ
cell
popul
differ
cell
surfac
marker
differ
cell
sourc
differ
abil
differenti
matur
endotheli
cell
vitro
vivo
critic
need
develop
consensu
definit
epc
particular
emphasi
function
capabl
cell
mesenchym
stromal
stem
cell
cell
stromal
origin
selfrenew
abil
differenti
varieti
cell
lineag
initi
describ
popul
bone
marrow
stromal
cell
first
describ
fibroblast
colonyform
unit
subsequ
marrow
stromal
cell
mesenchym
stem
cell
recent
multipot
mesenchym
stromal
cell
msc
msc
isol
wide
varieti
tissu
includ
umbil
cord
blood
wharton
jelli
placenta
adipos
tissu
lung
mesenchym
tissu
stem
cell
committe
intern
societi
cellular
therapi
isct
recent
updat
minim
criteria
defin
human
msc
tabl
msc
describ
differenti
varieti
matur
cell
type
may
also
immunomodulatori
properti
continu
increas
bodi
data
demonstr
efficaci
inflammatori
immunemedi
lung
injuri
diseas
model
suggest
potenti
role
inflammatori
immunemedi
lung
diseas
even
absenc
comprehens
understand
mechan
msc
act
particip
acknowledg
role
endogen
lung
progenitor
cell
cell
therapi
approach
lung
diseas
remain
time
excit
area
studi
nonetheless
mani
area
understand
process
mechan
remain
poorli
understood
recommend
area
continu
futur
investig
present
tabl
follow
review
current
literatur
extens
detail
session
present
confer
program
execut
summari
speaker
abstract
poster
session
includ
onlin
supplement
comprehens
summari
relev
publish
literatur
sinc
workshop
fall
present
pleas
see
report
previou
workshop
comprehens
review
previou
literatur
field
reader
also
refer
number
gener
review
specif
review
topic
publish
past
approxim
year
endogen
tissu
stem
cell
thought
contribut
tissu
mainten
repair
best
character
intestin
cell
rare
undifferenti
local
special
nich
within
tissu
tissuespecif
stem
cell
exhibit
selfrenew
capac
give
rise
daughter
cell
term
transit
amplifi
cell
turn
give
rise
special
differenti
cell
specif
organ
also
propos
differenti
cell
type
induc
mitot
activ
state
capac
cell
term
facult
progenitor
cell
facult
progenitor
cell
perform
gener
tissu
function
daili
basi
enter
mitot
cell
pool
tissu
injuri
repair
thu
facult
progenitor
cell
pool
function
larg
broadli
distribut
pool
repar
cell
supplement
repar
capac
tissu
stem
cell
altern
facult
progenitor
pool
may
serv
routin
tissu
homeostasi
regener
wherea
tissu
stem
cell
come
play
extrem
situat
injuri
topic
explor
sever
recent
review
remain
unclear
paradigm
hierarchi
describ
endogen
stem
progenitor
cell
organ
intestin
also
appli
lung
lung
complex
organ
contain
mani
distinct
cell
type
distribut
sever
differ
region
microenviron
along
pulmonari
tract
figur
consequ
wherea
identif
cell
prolifer
steadi
state
injuri
condit
rel
straightforward
character
classif
mitot
activ
put
endogen
stem
progenitor
cell
hierarchi
challeng
difficult
question
cell
arrang
hierarchi
hierarchi
cell
arrang
final
hierarchi
defin
characterist
cell
differ
level
hierarchi
differenti
prolifer
potenti
intestin
import
issu
specif
lung
might
includ
cell
cycl
time
frequenc
analys
interpret
potenti
stem
progenitor
cell
differ
region
lung
complic
lack
agreement
definit
terminolog
function
put
stem
cell
popul
continu
complic
field
despit
effort
come
agreement
terminolog
propos
list
terminolog
includ
report
confer
repeat
tabl
although
degre
consensu
propos
definit
still
disagr
ongo
debat
discuss
nonetheless
analys
lung
stem
progenitor
cell
anim
model
particularli
mous
led
import
advanc
past
year
seem
like
distinct
stem
andor
progenitor
cell
popul
maintain
specif
anatom
region
lung
figur
evid
distinct
airway
epitheli
progenitor
cell
popul
come
predominantli
studi
mice
data
prolifer
analys
speci
includ
hamster
rat
ferret
nonhuman
primat
human
much
evid
differ
airway
progenitor
cell
popul
hierarchi
also
come
studi
select
ablat
epitheli
cell
achiev
exposur
mice
toxic
chemic
naphthalen
naphthalen
select
deplet
facult
bronchiolar
progenitor
popul
clara
cell
wherea
exposur
deplet
upper
airway
cell
allow
assess
underli
basal
cell
facult
progenitor
recent
method
combin
genet
lineag
trace
evalu
differenti
potenti
put
stem
progenitor
cell
popul
analys
identifi
five
popul
airway
epitheli
cell
mous
abil
enter
cell
cycl
injuri
lung
thu
consid
facult
progenitor
cell
basal
claralik
clara
pulmonari
neuroendocrin
alveolar
type
cell
notabl
differ
fibrocyt
cell
subset
circul
leukocyt
produc
collagen
home
site
inflamm
ident
phenotyp
character
circul
fibrocyt
firmli
establish
epc
cell
express
cell
surfac
marker
mhc
ii
also
express
type
collagen
fibronectin
bronchiolar
stem
cell
term
appli
rare
popul
toxin
ie
naphthalen
resist
ccspexpress
cell
local
neuroepitheli
bodi
bronchoalveolar
duct
junction
rodent
lung
cell
prolifer
infrequ
steadyst
increas
prolif
rate
follow
deplet
transitamplifi
clara
cell
lineag
trace
studi
indic
cell
differenti
potenti
replenish
special
cell
type
bronchiolar
epithelium
human
correl
yet
identifi
bronchioalveolar
stem
cell
term
appli
small
popul
cell
locat
bronchoalveolar
duct
junction
mice
identifi
vivo
dual
label
ccsp
spc
resist
destruct
toxin
ie
naphthalen
cultur
dual
label
cell
also
express
self
renew
give
rise
progeni
express
either
ccsp
prospc
aquaporin
lead
specul
singl
cell
type
capac
differenti
bronchiolar
clara
cell
alveolar
type
pneumocyt
lineag
present
relationship
cell
studi
vitro
observ
dual
label
vivo
unclear
human
correl
yet
identifi
reprint
permiss
refer
clara
cell
claralik
cell
highlight
difficulti
identifi
facult
progenitor
cell
claralik
cell
cell
express
clara
cell
secretori
protein
ccsp
tracheobronchi
epithelium
rather
max
clara
origin
definit
clara
cell
specifi
termin
bronchiolar
locat
clear
ultrastructur
analys
epitheli
secretori
cell
throughout
proxim
distal
axi
howev
express
differ
repertoir
secret
protein
clara
claralik
cell
also
differenti
sensit
naphthalen
well
toxic
agent
importantli
proxim
claralik
cell
deriv
differ
progenitor
distal
airway
clara
cell
recent
data
suggest
mice
facult
progenitor
cell
pool
account
much
airway
epitheli
cell
replac
normal
homeostasi
also
significantli
contribut
tissu
repair
cellular
injuri
studi
also
basi
isol
put
stem
cell
use
flow
cytometr
analys
lung
homogen
sort
cell
surfac
marker
cell
popul
isol
manner
function
test
vitro
ectop
transplant
approach
suggest
cell
abil
regener
variou
popul
airway
andor
alveolar
cell
howev
reconstitut
healthi
injur
lung
final
critic
import
goal
lung
stem
cell
field
yet
achiev
trachea
larg
airway
compart
contain
two
major
epitheli
cell
lineag
basal
secretorycili
cell
subpopul
basal
epitheli
cell
previous
implic
tissu
stem
cell
basi
morpholog
combin
analysi
differenti
potenti
label
retent
lineag
trace
studi
suggest
cell
express
cytokeratin
could
serv
precursor
differenti
airway
epitheli
regener
follow
injuri
contrast
pulsechas
studi
demonstr
claralik
cell
serv
selfrenew
cell
type
progenitor
ciliat
airway
cell
rat
howev
lineag
trace
claralik
cell
demonstr
claralik
cell
replenish
cell
type
tracheal
proxim
airway
lack
consensu
whether
stem
cell
particip
repair
upper
airway
epithelium
reflect
part
failur
use
necessari
stem
cell
analysi
method
singl
studi
remain
signific
limit
field
howev
despit
use
multipl
injuri
model
vivo
includ
exposur
deterg
naphthalen
well
vitro
analys
suggest
subset
basal
cell
serv
role
either
tissu
stem
cell
facult
progenitor
cell
upper
airway
mice
furthermor
similar
conclus
deriv
use
human
cell
ex
vivo
vitro
cultur
system
overal
data
compart
still
limit
provid
strongest
evid
lung
tissuespecif
stem
cell
date
howev
question
remain
whether
classic
hierarchi
defin
intestin
hematopoiet
system
appli
lung
constrain
classic
model
data
present
yet
account
seem
reason
defin
model
work
lung
consid
possibl
differ
compart
lung
use
distinct
type
hierarchi
instanc
tracheobronchi
region
least
two
facult
progenitor
cell
pool
basal
cell
claralik
cell
steadi
state
take
care
lineag
howev
injuri
progenitorprogeni
relationship
chang
incorpor
data
revis
model
recogn
fact
data
support
role
lung
tissu
stem
cell
repair
come
experiment
system
extens
injuri
induc
may
provid
cohes
explan
lung
tissu
repair
mice
predomin
epitheli
cell
smaller
airway
noncili
clara
cell
exhibit
characterist
facult
progenitor
cell
injuri
ciliat
airway
epitheli
cell
howev
unlik
transitamplifi
cell
tissu
higher
rate
epitheli
turnov
intestin
clara
cell
exhibit
low
prolif
index
steadi
state
broadli
distribut
throughout
bronchiolar
epithelium
contribut
special
tissu
function
earlier
pulsechas
studi
identifi
clara
cell
progenitor
ciliat
cell
recent
experi
repeat
use
lineag
trace
method
latter
data
set
confirm
injuryrepair
studi
provid
new
observ
steadyst
clara
cell
selfrenew
clara
cell
function
progenitor
distal
airway
ciliat
cell
homeostasi
howev
increas
data
suggest
fundament
differ
claralik
clara
secretori
cell
proxim
versu
distal
airway
respect
thu
situat
complic
previous
appreci
anoth
wide
use
approach
clara
cellspecif
toxin
naphthalen
use
extens
deplet
bronchiolar
clara
cell
pool
toxin
metabol
cytochrom
isozym
found
clara
cell
parenter
treatment
ie
intraperiton
administr
result
dosedepend
deplet
clara
cell
popul
mice
popul
naphthaleneresist
cell
term
variant
clara
cell
vce
identifi
bronchiolar
stem
cell
vce
locat
within
discret
microenviron
includ
neuroepitheli
bodi
bronchoalveolar
duct
junction
bronchoalveolar
duct
junction
naphthaleneresist
clara
cell
stain
ccsp
prosurfact
protein
c
spc
howev
cell
shown
express
stem
cell
characterist
label
retent
interestingli
prospcccsp
dual
posit
cell
increas
number
naphthalen
injuri
compensatori
lung
growth
follow
unilater
pneumonectomi
mice
prospcccsp
dual
posit
cell
isol
use
method
develop
enrich
type
alveolar
epitheli
cell
duallabel
cell
exhibit
uniqu
cell
surfac
phenotyp
po
po
neg
neg
cell
found
prolifer
cultur
give
rise
progeni
express
ccsp
prospc
aquaporin
cell
term
bronchioalveolar
stem
cell
basc
howev
lineag
trace
method
demonstr
bronchiolar
alveolar
domain
distinct
normal
lung
contribut
lineag
tag
clara
cell
alveolar
epithelia
detect
steadi
state
homeostasi
hyperox
injuri
data
suggest
cultur
lung
progenitor
cell
may
assum
broader
spectrum
cell
phenotyp
vivo
counterpart
complex
bronchiolar
stem
cell
hierarchi
confound
method
use
identifi
evalu
put
stem
cell
importantli
presenc
abund
clara
cell
facult
progenitor
cell
pool
necessit
use
extrem
level
injuri
activ
put
stem
cell
thu
phenotyp
function
put
stem
cell
must
view
context
epitheli
injuri
collater
damag
tissu
type
system
effect
limit
number
differenti
cell
type
found
bronchiolar
region
clara
ciliat
pnec
made
difficult
distinguish
put
stem
cell
facult
progenitor
cell
complic
put
tissuespecif
stem
cell
quiescent
respons
injuri
ozon
deplet
ciliat
cell
pool
fact
bronchiolar
stem
cell
play
greater
role
normal
airway
epitheli
homeostasi
turnov
abund
pool
facult
progenitor
clara
cell
studi
suggest
neuroepitheli
bodyassoci
vce
like
function
reserv
popul
function
either
normal
mainten
relevantli
follow
deplet
facult
progenitor
pool
vce
nonetheless
addit
studi
need
confirm
clarifi
hypothesi
mous
well
human
lung
overal
possibl
variou
cell
thought
stem
progenitor
cell
properti
lung
repres
phenotyp
variant
cell
popul
divers
interpret
highlight
wide
recogn
need
marker
specif
function
distinct
cell
popul
precis
tool
lineag
trace
underscor
import
vivo
microenviron
cell
behavior
exampl
stem
cell
antigen
origin
describ
marker
murin
hematopoiet
stem
cell
describ
marker
put
bronchiolar
stem
cell
fibroblast
progenitor
cell
lung
notabl
two
recent
studi
use
flow
cytometr
purif
method
enrich
put
bronchiolar
stem
cell
mous
lung
first
suggest
naphthaleneresist
bronchiolar
progenitor
cell
put
bronchiolar
stem
cell
cell
surfac
phenotyp
low
autofluoresc
howev
studi
use
vitro
vivo
function
analys
thu
limit
interpret
second
studi
suggest
clonogen
bronchiolar
progenitor
cell
express
epcam
cocultur
cell
mesenchym
cell
promot
differenti
cell
signific
express
unknown
marker
typic
use
vivo
analys
thu
although
progress
made
clarifi
ident
role
bronchiolar
progenitor
cell
mice
role
cell
popul
normal
homeostasi
respons
sever
injuri
remain
unclear
moreov
littl
correspond
data
yet
exist
anim
model
human
lung
parallel
identif
lung
stem
progenitor
popul
recent
investig
explor
cell
signal
regulatori
mechan
manag
put
airway
progenitor
popul
mice
exampl
manipul
kra
mapk
protein
kinas
c
iota
pten
shown
induc
expans
bronchiolar
progenitor
bronchoalveolar
stem
cell
basc
number
also
enhanc
lung
tumorigenesi
cell
signal
pathway
wntbcatenin
hedgehog
notch
cell
implic
stem
cell
function
lung
tissu
howev
wherea
stimul
wntbcatenin
cell
signal
appear
promot
airway
submucos
gland
develop
inhibit
differenti
bronchiolar
stem
cell
lung
appear
play
key
role
mainten
repair
bronchiolar
epithelium
precis
role
pathway
endogen
lung
stem
progenitor
cell
remain
determin
possibl
remain
endogen
stem
progenitor
popul
exist
much
room
addit
inform
regulatori
mechan
pathway
elucid
epitheli
progenitor
cell
popul
although
attract
specul
lung
diseas
may
part
consequ
endogen
airway
stem
cell
failur
studi
need
draw
direct
connect
particular
littl
known
progenitor
cell
function
chronic
diseas
emphysema
suggest
inform
avail
genet
lung
diseas
cystic
fibrosi
cf
airway
epithelium
patient
cf
contain
cuboid
cell
express
primit
cell
marker
includ
thyroid
transcript
factor
cytokeratin
neuroepitheli
cell
also
express
cf
transmembran
conduct
regul
protein
cftr
defect
protein
patient
cf
appear
play
role
neuropeptid
secret
cftr
mice
contain
fewer
pulmonari
neuroendocrin
cell
embryon
develop
increas
number
cell
birth
observ
suggest
endogen
airway
progenitor
cell
pathway
cf
lung
may
alter
extens
investig
clarifi
question
alveolar
tissuespecif
stem
cell
remain
topic
less
well
explor
airway
defici
due
part
vast
repar
potenti
alveolar
compart
critic
role
ga
exchang
organ
viabil
alveolar
epitheli
repar
potenti
center
alveolar
type
ii
cell
aecii
long
held
concept
aecii
cell
precursor
aeci
cell
lack
aeciispecif
toxic
agent
limit
analysi
alveolar
stem
cell
issu
address
use
stem
cell
marker
develop
cell
type
cytotox
genet
strategi
neonat
mice
popul
put
progenitor
cell
express
ccsp
stem
cell
antigen
stagespecif
embryon
antigen
embryon
stem
cell
marker
identifi
cell
abl
form
epitheli
coloni
differenti
type
type
alveolar
epitheli
cell
howev
lineag
relationship
alveolar
type
cell
challeng
alveolar
type
cell
mitot
cell
type
vitro
indic
addit
studi
need
resolv
controversi
sever
studi
suggest
tissu
stem
cell
may
target
environment
agent
includ
pneumotroph
pathogen
airway
stem
progenitorlik
cell
suscept
infect
sever
acut
respiratori
syndrom
sar
viru
rais
possibl
endogen
lung
progenitor
cell
may
specif
diseas
target
compar
basal
epitheli
cell
trachea
upper
airway
appear
suscept
infect
common
cold
rhinoviru
howev
like
virus
sar
rhinoviru
target
wide
rang
respiratori
epitheli
cell
addit
progenitor
cell
endogen
progenitor
cell
may
also
attract
candid
target
gene
transfer
vector
provid
sustain
express
exampl
intratrach
administ
recombin
adenoassoci
vector
may
preferenti
target
vce
adult
mice
wherea
recombin
lentiviru
vector
administ
amniot
fluid
may
preferenti
target
airway
progenitor
fetal
mous
lung
less
inform
avail
regard
progenitor
cell
popul
maintain
cell
popul
interstiti
smooth
muscl
endotheli
cell
lung
recent
sever
group
identifi
appear
resid
mesenchym
stromal
stem
cell
mous
sheep
lung
well
human
nasal
mucosa
neonat
adult
human
lung
role
cell
might
play
repair
lung
tissu
immun
surveil
immunomodul
unclear
addit
role
endogen
lung
stem
progenitor
cell
repair
lung
injuri
increas
inform
suggest
matur
differenti
lung
cell
may
chang
phenotyp
respons
environment
challeng
andor
injuri
best
describ
alter
phenotyp
aecii
aeci
cell
vice
versa
epithelialmesenchym
transit
recogn
phenomenon
develop
howev
physiolog
pathophysiolog
role
adult
lung
remain
unclear
controversi
except
perhap
lung
cancer
develop
metastas
overal
major
challeng
remain
field
obviou
issu
develop
adequ
cellspecif
marker
lineag
trace
tool
exist
cell
typespecif
marker
particular
need
refin
increas
knowledg
obtain
inher
plastic
lung
cell
type
previous
identifi
lineag
deconstruct
issu
focu
recommend
nih
fund
agenc
previou
confer
continu
forefront
tabl
also
problem
remain
terminolog
methodolog
use
differ
laboratori
exampl
disagr
lack
consist
interpret
applic
seemingli
straightforward
terminolog
differenti
versu
undifferenti
special
versu
unspeci
continu
imped
progress
mention
list
suggest
terminolog
illustr
tabl
even
like
need
revis
near
futur
lung
cancer
stem
cell
intens
interest
connect
endogen
stem
progenitor
cell
cancer
stem
cell
cancer
stem
cell
defin
transplant
assay
cell
subset
capabl
propag
diseas
cell
frequent
term
tumor
initi
cell
hypothes
cell
maintain
tumor
progress
diseas
resist
cancer
stem
cell
best
describ
leukemia
breast
cancer
brain
cancer
increas
evid
suggest
lung
cancer
may
contain
rare
popul
cancer
stem
cell
studi
indic
differ
type
lung
cancer
initi
distinct
cell
type
lung
tumoriniti
cell
may
may
ident
cancer
stem
cell
maintain
establish
tumor
given
divers
lung
cancer
subtyp
may
surpris
purif
character
tumoriniti
cell
andor
cancer
stem
cell
import
aspect
studi
design
test
cancer
stem
cell
hypothesi
neg
side
popul
cell
identifi
sever
human
lung
cancer
cell
line
exhibit
tumorigen
properti
subcutan
implant
immunotoler
mice
side
popul
cell
also
identifi
clinic
lung
cancer
specimen
dual
posit
prospc
ccsp
posit
cell
bronchioalveolar
stem
cell
basc
discuss
section
also
suggest
tumoriniti
cell
number
recent
report
implic
cell
confer
resist
chemotherapi
tumor
initi
properti
recent
studi
begun
elucid
cell
signal
gene
express
pathway
includ
pten
protein
kinas
c
iota
wnt
hedgehog
ckit
akt
other
may
play
role
transform
endogen
progenitor
cell
lung
cancer
cell
howev
despit
grow
data
work
need
clarifi
connect
endogen
lung
progenitor
cell
potenti
role
lung
cancer
stem
cell
importantli
potenti
role
therapeut
target
bone
marrowderiv
circul
msc
epc
fibrocyt
may
contribut
develop
primari
metastat
lung
carcinoma
malign
mous
model
cell
function
part
provid
support
stroma
cancer
andor
particip
tumor
vascular
contrast
msc
epc
demonstr
home
area
tumor
develop
engin
epc
msc
well
hematopoiet
stem
cell
hsc
use
suppress
tumor
growth
mous
tumor
model
primari
lung
cancer
metastat
lung
cancer
cancer
metastat
lung
cell
base
treatment
may
thu
use
lung
cancer
therapeut
structur
engraft
number
public
past
approxim
year
initi
suggest
varieti
bone
marrowderiv
cell
includ
hematopoiet
stem
cell
hsc
mesenchym
stromal
stem
cell
msc
multipot
adult
progenitor
cell
mapc
popul
well
stem
progenitor
cell
isol
tissu
adipos
placenta
cord
blood
other
could
structur
engraft
matur
differenti
airway
alveolar
epitheli
cell
pulmonari
vascular
interstiti
cell
literatur
predominantli
base
studi
mice
use
techniqu
evalu
histolog
demonstr
donorderiv
marrow
cell
recipi
lung
system
administr
mark
donor
cell
green
flouresc
protein
gfp
label
cell
male
cell
femal
recipi
approach
usual
alway
myeloabl
recipi
mous
bone
marrow
review
refer
previou
lung
injuri
usual
necessari
observ
engraft
although
lung
injuri
alway
result
increas
appar
engraft
furthermor
myeloabl
regimen
use
usual
total
bodi
irradi
also
felt
contribut
lung
injuri
requir
evid
engraft
smaller
bodi
literatur
clinic
bone
marrow
lung
transplant
also
demonstr
vari
degre
appar
chimer
lung
transplant
recipi
review
ref
howev
whether
epitheli
engraft
fact
occur
signific
degre
remain
controversi
sever
technic
issu
contribut
misinterpret
result
initi
report
includ
inadequ
microscop
techniqu
donorderiv
cell
superimpos
resid
airway
alveolar
epitheli
cell
effect
discrimin
exquisit
care
sophist
microscop
approach
includ
confoc
deconvolut
techniqu
must
use
effect
demonstr
potenti
engraft
furthermor
varieti
leukocyt
notabl
airway
alveolar
macrophag
resid
lung
mani
earli
report
use
antibodi
direct
leukocyt
marker
exclud
possibl
cell
donor
origin
detect
airway
alveolar
epithelium
donorderiv
leukocyt
rather
epitheli
cell
tool
use
gfp
marker
donorderiv
marrow
cell
obtain
transgen
gfp
mice
recipi
mous
lung
subject
error
presenc
autofluoresc
cell
commonli
found
lung
nonetheless
better
understand
better
approach
possibl
confound
factor
discuss
report
suggest
engraft
donorderiv
airway
andor
alveolar
epithelium
occur
low
level
perturb
airway
alveolar
epithelium
model
lung
injuri
observ
msc
bone
marrow
cord
blood
origin
side
popul
cell
plastic
adher
marrow
stromal
cell
full
marrow
transplant
myeloabl
regimen
studi
tend
use
sophist
microscop
analyt
techniqu
nonetheless
epitheli
engraft
gener
rare
except
condit
discuss
parallel
recent
studi
also
continu
demonstr
rare
appar
engraft
pulmonari
interstitium
vasculatur
total
marrow
transplant
varieti
injuri
model
report
suggest
engraft
lung
tissu
circul
donorderiv
cell
occur
certain
condit
usual
follow
previou
perturb
induct
lung
injuri
howev
mani
variabl
yet
explor
may
increas
epitheli
interstiti
pulmonari
vascular
engraft
circul
donorderiv
cell
vigor
injuri
regimen
serial
naphthalen
administr
deplet
airway
epitheli
cell
coupl
busulfan
suppress
endogen
bone
marrow
appear
increas
engraft
exogen
administ
bone
marrow
cell
compar
sever
report
suggest
chronic
progress
lung
injuri
may
result
substanti
engraft
aecii
cell
interstiti
pulmonari
vascular
cell
donorderiv
cell
mous
rat
model
howev
chronic
lung
injuri
model
result
substanti
engraft
effect
age
either
donor
cell
recipi
also
less
wellexplor
although
transplant
whole
marrow
mous
pup
use
varieti
condit
regimen
increas
number
bone
marrowderiv
cell
observ
administr
total
marrow
adult
mice
rout
administr
donorderiv
cell
also
less
wellcharacter
studi
investig
engraft
system
administr
donor
cell
direct
intratrach
administr
msc
marrowderiv
cell
appear
result
appar
epitheli
engraft
howev
level
appar
engraft
variabl
initi
engraft
observ
sustain
type
stemprogenitor
cell
fulli
differenti
nonpulmonari
cell
might
engraft
lung
epithelium
interstitium
pulmonari
vasculatur
remain
fulli
explor
addit
exist
studi
hsc
msc
bone
marrow
cord
blood
placent
tissu
origin
epc
fibrocyt
possibl
remain
may
cell
popul
could
recruit
lung
local
lung
system
rout
administr
exampl
two
differ
popul
cell
isol
human
amniot
tissuehuman
amniot
epitheli
cell
haec
popul
multipot
cell
term
human
amniot
fluid
stem
cell
hafsc
describ
appar
engraft
limit
amount
mous
lung
hafsc
local
distal
airway
express
thyroid
transcript
factor
surfact
protein
c
spc
wherea
haec
local
distal
airway
area
lung
injuri
express
rang
surfact
protein
notabl
administr
haec
bleomycininjur
immunocompet
mice
result
abrog
lung
injuri
without
appar
host
respons
cell
compar
haec
administ
rat
experiment
induc
myocardi
infarct
abl
reduc
extent
infarct
also
appar
acquir
phenotyp
characterist
cardiomyocyt
suggest
cell
may
use
xenogen
model
lung
injuri
may
also
exhibit
paracrin
effect
modul
lung
injuri
topic
discuss
section
mesenchym
stromal
cell
popul
circul
bone
marrowderiv
cytokeratin
cell
describ
particip
reepitheli
denud
tracheal
xenograft
recent
report
also
describ
popul
ccspexpress
adult
marrow
cell
appear
robustli
lodg
engraft
lung
either
system
intratrach
administr
figur
sourc
stem
progenitor
cell
adipos
tissu
also
extens
character
abil
engraft
lung
tissu
bone
marrow
cord
blood
origin
cell
howev
abil
structur
engraft
adult
lung
may
sole
properti
stem
progenitor
cell
intratrach
administr
neonat
mous
lung
fibroblast
result
appar
alveolar
interstiti
engraft
engraft
higher
area
elastaseinduc
lung
injuri
intratach
administr
fibroblast
transduc
express
mitig
acut
lung
injuri
inflamm
mice
compar
intratrach
administr
aecii
cell
result
rare
engraft
area
injur
lung
administ
bleomycin
rat
notabl
bleomycininjur
rat
receiv
aecii
cell
less
histolog
injuri
decreas
hydroxyprolin
content
recent
aecii
cell
deriv
vitro
human
embryon
stem
cell
abl
engraft
mitig
bleomycininduc
lung
injuri
mice
result
suggest
lung
injuri
might
amen
varieti
cell
therapi
approach
studi
robust
evid
engraft
suggest
potenti
role
fusion
still
fulli
elucid
bone
marrowderiv
cell
induc
fuse
lung
epitheli
cell
vitro
vivo
investig
suggest
fusion
rare
occurr
one
studi
suggest
fusion
donorderiv
marrow
cell
aecii
cell
occur
mous
lung
chromosom
may
lost
result
heterokaryon
cell
nonetheless
fusion
exogen
administ
cell
resid
lung
cell
thought
rare
occurr
uncertain
physiolog
signific
mechan
circul
system
administ
stem
progenitor
cell
might
recruit
lung
remain
poorli
understood
number
studi
demonstr
system
administr
cell
initi
local
lung
lung
injuri
result
increas
local
andor
retent
marrowderiv
cell
lung
whether
repres
format
cell
emboli
lung
specif
adher
pulmonari
vascular
adhes
molecul
remain
unclear
anoth
studi
embol
system
administ
msc
lung
felt
result
secret
antiinflammatori
protein
time
cell
administr
lung
injuri
also
influenc
recruit
phenotyp
convers
system
administr
msc
hour
lung
irradi
result
appar
engraft
cell
epitheli
vascular
endotheli
cell
howev
msc
administ
later
time
point
appear
engraft
interstiti
cell
particip
develop
fibrosi
recipi
immun
respons
also
play
signific
yet
poorli
character
role
retent
cell
lung
commonli
use
approach
sexmismatch
transplant
cell
administr
may
also
result
clearanc
cell
rang
ident
chemotact
solubl
mediat
releas
injur
lung
cell
role
upregul
adhes
molecul
circul
cell
might
interact
remain
poorli
understood
review
engraft
number
factor
includ
age
donor
recipi
type
cell
administ
rout
administr
forth
might
affect
recruit
cell
lung
compar
mechan
stem
progenitor
cell
isol
adult
tissu
might
induc
acquir
phenotyp
lung
epitheli
interstiti
vascular
endotheli
cell
remain
poorli
understood
vitro
studi
demonstr
solubl
factor
releas
lung
epitheli
cell
injur
lung
homogen
induc
express
lung
epitheli
marker
sever
type
marrowderiv
cell
possibl
activ
bcatenin
cellsign
pathway
compar
cocultur
embryon
stem
cell
fetal
pulmonari
mesenchym
promot
develop
cell
express
phenotyp
marker
lung
epitheli
cell
one
novel
mechan
induc
phenotyp
chang
might
involv
releas
membranederiv
microvesicl
recent
appreci
mean
intercellular
commun
involv
horizont
transfer
mrna
protein
cell
nonetheless
despit
continu
interest
possibl
engraft
exogen
cell
lung
emphasi
move
area
notabl
immumomodulatori
effect
administ
cell
ex
vivo
tissu
engin
endotheli
progenitor
cell
past
decad
circul
bone
marrowderiv
cell
put
similar
embryon
angioblast
identifi
term
endotheli
progenitor
cell
epc
cell
report
exhibit
potenti
prolifer
differenti
matur
endotheli
cell
increas
evid
demonstr
epc
play
role
pathogenesi
wide
varieti
lung
diseas
includ
pulmonari
hypertens
pulmonari
fibrosi
airway
diseas
includ
asthma
copd
acut
lung
injuri
lung
cancer
recent
bronchopulmonari
dysplasia
obstruct
sleep
apnea
children
howev
studi
epc
lung
diseas
hamper
lack
consensu
regard
identif
cell
earli
investig
reli
almost
exclus
use
flow
cytometri
conjunct
immunostain
identifi
enumer
cell
bone
marrow
well
circul
furthermor
similar
techniqu
use
differ
studi
differ
group
marker
use
lack
uniqu
cell
surfac
maker
identifi
epc
continu
complic
compar
assess
similar
diseas
process
result
grow
consensu
field
encourag
use
function
assay
vitro
vivo
conjunct
use
flow
cytometri
immunohistochemistri
ihc
enumer
epc
better
character
true
abil
form
function
endothelium
critic
area
futur
studi
remain
develop
consensusbas
approach
definit
use
epc
particular
emphasi
function
capabl
cell
present
appear
two
major
type
epc
isol
human
peripher
blood
differenti
cultur
approach
avoid
prior
certainti
surfac
select
marker
epc
first
term
earli
epc
character
earli
growth
vitro
posit
inabl
form
tube
matrigel
tube
form
assay
high
level
cytokin
secret
cell
known
deriv
hematopoiet
lineag
differenti
along
myeloid
lineag
respons
certain
cytokin
chemokin
type
epc
term
late
outgrowth
epc
outgrowth
endotheli
cell
oec
endotheli
coloni
form
cell
ecfc
character
posit
lack
express
uniqu
abil
spontan
form
human
blood
vessel
implant
gel
immunodefici
mice
inoscul
murin
vessel
becom
part
system
circul
cell
type
may
uniqu
potenti
lung
microvascular
repair
earli
epc
role
paracrin
cell
late
epc
function
specif
restor
vascular
structur
lung
intraven
infus
type
cell
anim
model
demonstr
abil
preferenti
local
lung
two
epc
type
may
synergist
role
restor
vascular
structur
function
infus
togeth
character
two
epc
type
includ
method
enhanc
number
ex
vivo
could
implic
develop
therapi
specif
phenotyp
abnorm
given
lung
diseas
addit
sourc
epc
exampl
adult
peripher
blood
versu
umbil
cord
blood
may
also
influenc
differenti
potenti
epc
schemat
summari
current
classif
character
human
epc
depict
figur
number
circul
epc
correl
varieti
clinic
variabl
sever
lung
diseas
state
demonstr
potenti
util
epc
biomark
although
increas
circul
epc
number
correl
surviv
acut
lung
injuryacut
respiratori
distress
syndrom
aliard
associ
less
residu
lung
damag
patient
pneumonia
increas
number
necessarili
correl
better
outcom
normal
physiolog
lung
diseas
exampl
decreas
number
circul
epc
patient
copd
associ
abnorm
spirometri
although
differ
studi
show
level
circul
epc
invers
correl
copd
diseas
sever
increas
number
circul
epc
also
portend
wors
surviv
among
nonsmal
cell
lung
cancer
asthma
number
circul
epc
increas
compar
nonasthmat
control
subject
correl
clinic
outcom
sever
clinic
factor
implic
mobil
epc
mechan
effect
begun
elucid
hypoxia
appear
stimulu
epc
mobil
recruit
wherea
hyperoxia
correl
decreas
circul
epc
particularli
preterm
epc
featur
may
play
role
bronchopulmonari
dysplasia
prematur
infant
neonat
expos
high
oxygen
level
also
suggest
epc
could
contribut
lung
repair
acut
lung
injuri
recent
studi
demonstr
system
administr
popul
bone
marrowderiv
angiogen
cell
improv
lung
alveolar
architectur
neonat
hyperoxia
exposur
rat
degre
engraft
observ
unclear
structur
contribut
engraft
cell
rather
paracrin
growth
stimul
effect
respons
defect
lung
develop
defect
lung
repair
set
protract
inflamm
injuri
may
result
part
inadequ
contribut
local
circul
epc
age
previous
report
invers
correl
epc
number
also
abil
epc
home
ischem
tissu
base
age
may
mediat
inabl
age
tissu
normal
activ
hypoxiainduc
amedi
hypoxia
respons
use
hmgcoa
reductas
inhibitor
demonstr
benefici
effect
mobil
epc
may
relat
effect
class
drug
prevent
epc
apoptosi
respons
noxiou
stimuli
includ
effect
tnfa
therebi
enhanc
epc
surviv
differenti
pathway
recent
implic
mobil
epc
includ
circul
vascular
endotheli
growth
factor
vegf
hypoxiainduc
releas
insulinlik
growth
factor
may
also
play
promin
role
epc
home
goal
increas
number
epc
develop
method
enhanc
mobil
may
appropri
diseas
affect
lung
particularli
lung
cancer
although
level
circul
epc
may
serv
biomark
diseas
progress
sever
epc
may
effect
develop
lung
tumor
vasculatur
home
site
lung
metastas
well
cancer
neovascular
involv
recruit
epc
bone
marrow
cell
logic
target
antiangiogenesi
therapi
exampl
investig
drug
tk
kringl
domain
tissuetyp
plasminogen
activ
demonstr
use
block
adhes
differenti
migrat
ex
vivo
human
epc
vitro
also
decreas
tumor
growth
vascular
scid
mous
tumor
model
find
suggest
block
epc
could
import
therapi
prevent
cancer
progress
addit
system
inject
epc
local
lung
appear
home
metastat
tumor
lung
yet
poorli
understood
mechan
suggest
modif
epc
express
suicid
gene
therapeut
molecul
could
potenti
use
cellbas
therapi
approach
lung
cancer
mechan
control
mobil
home
epc
lung
remain
poorli
understood
subject
intens
investig
number
studi
mice
dog
demonstr
role
exogen
administ
epc
vasculogenesi
vascular
repair
experiment
model
pulmonari
hypertens
furthermor
epc
transduc
express
proangiogen
factor
endotheli
nitric
oxid
synthetas
eno
inhibitor
smooth
muscl
cell
prolifer
calcitonin
generel
peptid
appear
home
site
endotheli
damag
lung
injuri
epc
also
preferenti
local
area
injur
lung
system
administr
may
also
paracrin
effect
decreas
inflamm
two
pilot
trial
autolog
epc
administr
primari
pulmonari
hypertens
conduct
zhejiang
univers
hangzhou
china
adult
pediatr
patient
demonstr
increas
walk
capac
improv
hemodynam
variabl
includ
mean
pulmonari
arteri
pressur
pulmonari
vascular
resist
cardiac
output
week
system
administr
autolog
epc
convent
therapi
compar
patient
receiv
convent
therapi
alon
importantli
advers
effect
epc
administr
note
although
longterm
followup
pend
therapeut
trial
administr
autolog
earli
outgrowth
epc
transduc
express
eno
patient
pulmonari
hypertens
pulmonari
hypertens
cell
therapi
phacet
trial
initi
st
michael
hospit
toronto
jewish
gener
hospit
montreal
march
phacet
trial
complet
enrol
first
two
dosepanel
three
patient
receiv
total
million
earli
growth
epc
transfect
overexpress
human
eno
panel
three
patient
receiv
million
cell
panel
inform
courtesi
duncan
stewart
md
frcpc
univers
ottawa
cell
deliveri
procedur
well
toler
safeti
concern
notabl
first
six
patient
show
remark
reduct
total
pulmonari
vascular
resist
pvr
cours
deliveri
period
might
repres
effect
increas
releas
engin
epc
within
pulmonari
microcircul
trial
data
safeti
monitor
board
approv
move
panel
call
total
million
cell
three
divid
dose
day
complet
third
dose
panel
follow
enrol
addit
three
patient
highest
toler
cell
dose
provid
suffici
support
move
forward
design
random
control
trial
assess
potenti
efficaci
cell
therapi
approach
pulmonari
arteri
hypertens
pah
go
forward
clarif
specif
cell
type
involv
process
neoangiogenesi
result
less
confus
surround
term
epc
appar
earli
outgrowth
cell
hematopoiet
deriv
identifi
classic
cell
surfac
marker
morpholog
vitro
hematopoiet
colonyform
activ
vivo
reconstitut
blood
lineag
immunodefici
mice
contrast
ecfc
oec
rare
endotheli
cell
display
clonal
prolif
capac
vivo
vessel
form
abil
discrimin
sever
cell
surfac
antigen
hematopoiet
subset
role
b
lymphocyt
macrophag
dendrit
cell
red
blood
cell
andor
product
neoangiogenesi
process
also
describ
thu
go
forward
rather
use
nondescript
term
epc
field
may
wish
consid
use
terminolog
best
describ
cell
popul
investig
specif
cell
patient
point
time
involv
particular
aspect
neoangiogen
process
circul
fibrocyt
circul
fibrocyt
first
describ
subset
circul
leukocyt
produc
collagen
home
site
inflamm
ident
phenotyp
character
circul
fibrocyt
firmli
establish
cell
describ
cell
surfac
marker
mhc
ii
also
express
type
collagen
fibronectin
circul
fibrocyt
implic
pathogenesi
sever
lung
diseas
includ
mous
clinic
model
pulmonari
fibrosi
pulmonari
hypertens
subepitheli
fibrosi
develop
sever
asthma
clinic
bronchiol
obliteran
patient
lung
bone
marrow
transplant
level
circul
fibrocyt
may
indic
wors
prognosi
ipf
interestingli
number
circul
fibrocyt
highest
patient
experienc
acut
exacerb
number
return
baselin
recoveri
sever
chemokin
includ
stromal
deriv
axe
implic
recruit
circul
fibrocyt
fibrot
lung
overal
mechan
fibrocyt
recruit
lung
poorli
understood
matrix
metalloproteinas
express
may
also
involv
recruit
fibrocyt
injur
posttranspl
lung
similarli
mechan
fibrocyt
induc
undergo
phenotyp
transform
fibroblast
myofibroblast
contribut
fibrogenesi
lung
poorli
understood
although
haptoglobin
cysteinyl
leukotrien
implic
hypoxia
potent
stimulu
releas
varieti
factor
pulmonari
vascular
endothelium
serv
recruit
fibrocyt
well
induc
phenotyp
convers
fibroblast
myofibroblast
notabl
deplet
circul
fibrocyt
abrog
hypoxiainduc
perivascular
remodel
rat
circul
fibroblast
may
also
import
lung
cancer
develop
metastasi
circul
fibrocyt
precursor
found
blood
lung
cancer
patient
contribut
tumor
develop
system
administ
nod
scid
mice
engraft
human
lung
cancer
xenograft
bone
marrowderiv
cell
may
also
contribut
fibroblast
myofibroblast
tumor
stromal
tissu
result
suggest
specif
inhibit
fibrocyt
use
drug
deliveri
vehicl
may
also
import
therapeut
target
pulmonari
vascular
diseas
mesenchym
stromal
stem
cell
msc
first
describ
adher
clonogen
nonphagocyt
fibroblasticlik
popul
bone
marrow
cell
nomenclatur
chang
year
msc
initi
term
fibroblast
coloni
form
unit
subsequ
marrow
stromal
cell
mesenchym
stem
cell
recent
multipot
mesenchym
stromal
cell
msc
msc
isol
wide
varieti
tissu
includ
umbil
cord
blood
wharton
jelli
placenta
adipos
tissu
recent
cell
characterist
suggest
ident
msc
isol
adult
mous
lung
human
nasal
mucosa
lung
human
neonat
human
lung
transplant
recipi
human
lung
msc
appear
immunomodulatori
capabl
similar
bone
marrowderiv
msc
wherea
ovalbumin
sensit
challeng
increas
number
lung
msc
mice
suggest
lung
msc
may
involv
regul
local
inflammatori
immun
respons
howev
exact
ident
physiolog
role
put
lung
msc
yet
clear
multipot
progenitor
popul
describ
lung
speci
exact
identifi
role
cell
also
well
understood
howev
definit
investig
msc
continu
confound
sever
issu
msc
isol
differ
sourc
gener
express
compar
cell
surfac
marker
differenti
along
recogn
lineag
pathway
howev
differ
gene
express
lineag
tendenc
properti
describ
among
msc
isol
differ
sourc
epc
mani
publish
studi
use
differ
definit
character
msc
complic
compar
assess
publish
studi
mesenchym
tissu
stem
cell
committe
intern
societi
cellular
therapi
isct
defin
minim
criteria
defin
human
msc
tabl
hope
rigor
adher
criteria
help
focu
compar
investig
potenti
use
lung
diseas
furthermor
fibroblast
also
describ
capabl
exhibit
properti
consist
msc
adult
mous
lungsid
popul
cell
includ
differenti
abil
well
immunomodulatori
activ
discuss
field
msc
complic
number
factor
one
signific
differ
among
msc
differ
speci
mous
msc
bone
marrow
particularli
difficult
earli
cultur
grow
slowli
heavili
contamin
hematopoiet
cell
usual
requir
immunoselect
remov
review
ref
expans
cell
pass
crisi
cultur
propag
rapidli
surviv
cell
transform
becom
tumorigen
addit
msc
differ
mous
strain
differ
requir
medium
optim
growth
differ
surfac
epitop
featur
present
signific
obstacl
mani
potenti
import
experi
mous
model
diseas
transgen
mice
featur
murin
msc
frequent
account
public
cell
term
mesenchym
stem
cell
msc
use
result
mani
import
observ
long
list
public
difficult
interpret
within
context
msc
biolog
therapeut
msc
rat
bone
marrow
also
present
unusu
featur
includ
strain
differ
rapid
initi
growth
tendenc
coloni
shed
cell
gener
new
coloni
also
rat
mous
msc
tendenc
develop
genom
instabl
extens
expans
present
human
msc
bone
marrow
best
character
msc
also
present
challeng
featur
earli
passag
cell
plate
low
densiti
enrich
small
rapidli
replic
cell
highli
clonogen
high
potenti
differenti
howev
coloni
form
msc
sever
surpris
featur
cell
within
clonal
singlederiv
coloni
becom
heterogen
coloni
expand
cell
inner
region
express
differ
profil
gene
cell
outer
region
coloni
form
reclon
cell
singl
coloni
gener
new
coloni
heterogen
size
differenti
potenti
also
cell
within
clonal
singlederiv
coloni
becom
heterogen
coloni
expand
cell
inner
region
express
differ
profil
gene
cell
outer
region
human
msc
extens
expand
high
densiti
retain
properti
low
densiti
cultur
enrich
larg
slowli
propag
cell
diminish
clonogen
differenti
potenti
complic
parallel
prepar
msc
bone
marrow
aspir
isol
normal
donor
session
differ
featur
rate
propag
potenti
differenti
addit
cultur
variabl
includ
cultur
surfac
composit
stiff
oxygen
environ
mechan
forc
temperatur
factor
cultur
densiti
profoundli
influenc
phenotyp
behavior
msc
includ
cultur
threeversu
twodimension
scaffold
discuss
section
lung
bioengin
discuss
research
msc
confus
mark
differ
msc
mice
human
msc
term
properti
cell
surfac
epitop
eas
expans
genom
stabil
also
becom
increasingli
appar
differ
inflammatori
environ
profoundli
influenc
msc
behavior
furthermor
grow
evid
msc
heterogen
differ
msc
subtyp
exist
address
variat
properti
cultur
msc
ncrrnihsponsor
center
offer
standard
prepar
murin
human
msc
investig
use
benchmark
preclin
experi
http
medicinetamhsceduirmmscdistributionhtml
nonetheless
despit
issu
substanti
progress
continu
made
msc
lung
injuri
repair
initi
emphasi
potenti
abil
msc
acquir
epitheli
phenotyp
engraft
structur
lung
cell
howev
despit
abil
induc
express
marker
express
either
airway
alveolar
epitheli
cell
vitro
cultur
system
engraft
msc
cell
type
investig
far
rare
event
uncertain
physiolog
signific
lung
emphasi
increasingli
shift
toward
profound
immunomodulatori
antiinflammatori
nonimmunogen
properti
msc
msc
abil
regul
hematopoiet
cell
secret
multipl
regulatori
molecul
growth
factor
antiinflammatori
cytokin
modul
immun
inflammatori
respons
review
msc
also
inhibit
prolifer
function
broad
rang
immun
cell
includ
cell
b
cell
natur
killer
nk
cell
dendrit
cell
dc
vitro
model
system
figur
notabl
msc
inhibit
lymphocyt
prolifer
activ
cytokin
releas
respons
either
alloantigen
mitogen
stimuli
dosedepend
direct
suppress
effect
prolifer
mechan
msc
inhibit
immun
effector
cell
prolifer
function
vitro
partli
understood
direct
cellcel
contact
well
releas
solubl
mediat
propos
figur
msc
also
describ
capac
act
antigenpres
cell
vitro
model
system
properti
influenc
exposur
ifng
tgfb
furthermor
msc
may
also
affect
action
cell
involv
innat
immun
respons
notabl
macrophag
also
becom
increasingli
appar
differ
inflammatori
environ
profoundli
influenc
msc
behavior
msc
express
wide
varieti
chemokin
cytokin
receptor
includ
tnfa
ifng
receptor
particular
express
high
abund
describ
prolif
stimulu
msc
express
mhc
costimulatori
molecul
alter
exposur
inflammatori
mediat
commonli
found
vivo
ifng
tgfb
chemotaxi
migrat
toward
wide
varieti
mediat
includ
tnfa
macrophag
migrat
inhibitori
factor
mif
tgfb
hepatocyt
growth
factor
hgf
other
describ
express
specif
cell
surfac
molecul
includ
marck
implic
direct
msc
chemotaxi
msc
also
express
tolllik
receptor
includ
endotoxin
receptor
activ
tlr
msc
produc
wide
varieti
effect
mani
still
elucid
furthermor
express
trl
msc
influenc
number
factor
includ
exposur
bacteri
toxin
varieti
inflammatori
mediat
hypoxia
characterist
mani
lung
injuri
diseas
also
alter
msc
express
cell
surfac
molecul
secret
solubl
mediat
msc
overal
illustr
rapidli
grow
bodi
evid
demonstr
msc
malleabl
significantli
influenc
local
inflammatori
environ
includ
found
lung
injuri
msc
also
seem
rel
nonimmunogen
due
low
constitut
express
major
histocompat
complex
mhc
type
lack
constitut
express
mhc
type
costimulatori
molecul
review
ref
allow
administr
allogen
msc
without
signific
host
respons
although
frequenc
msc
adult
bone
marrow
low
less
isol
bone
marrow
tissu
msc
expand
ex
vivo
make
possibl
manufactur
cell
potenti
therapeut
purpos
msc
also
rel
easili
transduc
genet
manipul
deliv
secret
select
diseasemodifi
molecul
overal
properti
msc
make
attract
potenti
therapeut
tool
vector
deliveri
diseasespecif
treatment
substanc
immunomodulatori
agent
msc
use
clinic
trial
inflammatori
autoimmun
diseas
graft
versu
host
crohn
diseas
well
acut
myocardi
infarct
one
import
find
come
publish
data
administr
msc
appear
safe
well
toler
even
sever
ill
patient
although
longterm
effect
msc
administr
unknown
appear
signific
shortterm
effect
context
steadili
increas
number
articl
demonstr
efficaci
either
system
intratrach
msc
administr
grow
spectrum
lung
injuri
model
mice
includ
mous
model
acut
lung
injuri
fibrosi
sepsi
pulmonari
hypertens
ischemia
reperfus
injuri
bronchopulmonari
dysplasia
bronchiol
obliteran
asthma
copd
pulmonari
diseas
summar
tabl
msc
also
demonstr
efficaci
model
primari
metastat
lung
cancer
recent
studi
also
demonstr
efficaci
msc
administr
endotoxininjur
human
lung
explant
although
mechan
msc
effect
complet
understood
solubl
mediat
releas
msc
appear
play
import
role
amelior
acut
fibrot
injuri
differ
model
implic
differ
model
system
includ
receptor
antagonist
keratinocyt
growth
factor
kgf
hepatocyt
growth
factor
hgf
angiopoietin
tgfb
transduct
msc
express
either
kgf
decreas
endotoxinmedi
lung
injuri
presum
abrog
endotoxinmedi
endotheli
injuri
msc
appear
also
act
part
decreas
increas
endotheli
permeabl
found
acut
lung
injuri
also
secret
antibacteri
peptid
msc
may
also
exert
effect
lung
inflamm
injuri
primari
interact
immun
system
rather
direct
action
lung
exampl
grow
bodi
evid
suggest
msc
amelior
allerg
airway
inflamm
mice
promot
phenotyp
vivo
antigenspecif
cell
circul
antigenspecif
immunoglobulin
mean
abrog
lung
injuri
msc
appear
capabl
spectrum
effect
differ
lung
injuri
howev
note
earlier
discuss
msc
mani
studi
discuss
use
differ
prepar
msc
detail
tabl
rang
popul
heterogen
plastic
adher
adipos
stromal
cell
purifi
wellcharacter
bone
marrowderiv
msc
obtain
core
facil
ncrrnihsponsor
texa
formerli
tulan
center
prepar
distribut
adult
stem
cell
msc
http
medicinetamhsceduirmmscdistributionhtml
furthermor
differ
syngen
allogen
xenogen
msc
administr
less
well
explor
lung
injuri
model
wherea
overal
consist
studi
demonstr
abil
msc
amelior
differ
type
lung
injuri
encourag
rigor
must
appli
understand
mechan
msc
effect
compar
msc
isol
differ
protocol
obtain
differ
tissu
sourc
specif
msc
effect
compar
potenti
antiinflammatori
immunomodulatori
effect
stromal
cell
fibroblast
must
care
consid
tabl
exampl
system
administr
primari
dermal
fibroblast
similarli
decreas
ragwe
pollen
ovalbumininduc
allerg
airway
inflamm
msc
fibroblast
transduc
express
decreas
acut
endotoxininduc
lung
injuri
howev
intratrach
administr
fibroblast
mimic
effect
msc
amelior
endotoxininduc
acut
lung
injuri
result
suggest
msc
stromal
cell
fibroblast
may
share
similar
antiinflammatori
mechan
howev
fibroblast
also
heterogen
depend
part
tissu
sourc
thu
potenti
antiinflammatori
effect
may
differ
depend
origin
fibroblast
less
like
degre
low
immunogen
msc
provok
lung
inflamm
nonetheless
comparison
msc
fibroblast
differ
injuri
model
like
provid
import
insight
antiinflammatori
mechan
msc
import
includ
appropri
cell
control
fibroblast
assess
msc
effect
differ
lung
injuri
model
msc
also
increasingli
describ
vehicl
deliveri
therapeut
gene
protein
notabl
msc
home
tumor
unclear
mechan
serv
vehicl
deliveri
chemotherapeut
antitumor
agent
recent
describ
mous
lung
tumor
model
may
provid
viabl
therapi
lung
cancer
notabl
human
bone
marrowderiv
msc
engin
express
tumor
necrosi
factorrel
apoptosi
induc
ligand
trail
found
significantli
clear
tumor
metastas
xenograft
model
metastat
human
lung
cancer
mice
compar
human
umbil
cord
blood
msc
engin
express
ifnb
found
significantli
attenu
human
bronchioalveolar
carcinoma
xenograft
mice
contrast
msc
may
also
contribut
tumor
stroma
influenc
behavior
cancer
cell
recent
report
demonstr
human
msc
administr
could
promot
growth
pulmonari
metastas
mous
model
primari
human
osteosarcoma
whether
marrowderiv
cell
contribut
develop
epitheli
cancer
remain
activ
area
investig
addit
caution
regard
system
administr
msc
rais
previou
confer
report
repeat
cultur
strategi
use
fetal
bovin
calf
serum
despit
wash
cell
prior
system
administr
bovin
antigen
may
remain
adher
cell
surfac
trigger
immun
reaction
well
decreas
potenti
engraft
recipi
mice
patient
cultur
msc
medium
lower
calf
serum
content
use
heterolog
speciesspecif
serum
altern
serum
substitut
platelet
lysat
remov
calf
serum
antigen
administr
propos
strategi
decreas
potenti
advers
effect
addit
intraven
administr
msc
initi
lodg
lung
vasculatur
move
pulmonari
capillari
system
organ
howev
depend
prepar
regimen
use
msc
clump
potenti
lodg
emboli
lung
capillari
pretreat
mice
vasodil
sodium
nitroprussid
propos
mechan
decreas
msc
cell
trap
pulmonari
capillari
whether
msc
may
undergo
malign
transform
remain
topic
consider
debat
concern
murin
msc
extens
expand
cultur
mani
passag
develop
chromosom
instabl
produc
lung
sarcoma
mice
result
emphas
greater
propens
mous
msc
acquir
chromosom
abnorm
serial
passag
cultur
howev
extens
cultur
almost
mammalian
cell
cultur
lead
crisi
follow
immort
transform
tumorigen
cell
well
document
mous
fibroblast
concern
potenti
tumorigen
human
msc
rais
three
report
describ
escap
senesc
gener
malign
cell
msc
expand
cultur
report
unexpect
insofar
emerg
senesc
observ
laboratori
studi
cell
decad
discrep
larg
explain
report
two
laboratori
indic
cultur
human
msc
cross
contamin
human
fibrosarcoma
osteosarcoma
cell
line
highlight
need
develop
better
marker
defin
msc
import
need
verifi
ident
cell
even
receiv
establish
sourc
anticip
addit
strategi
maxim
therapeut
use
msc
decreas
chanc
advers
effect
develop
next
sever
year
pro
con
move
toward
clinic
trial
msc
cell
type
epc
vigor
debat
three
confer
date
anticip
debat
continu
nonetheless
clinic
data
accumul
phase
doubleblind
placebocontrol
trial
prochym
ex
vivo
cultur
adult
human
mesenchym
stem
cell
conduct
osiri
therapeut
inc
columbia
md
patient
acut
myocardi
infarct
improv
fev
fvc
note
treat
patient
although
mechan
improv
pulmonari
function
patient
popul
yet
understood
observ
stimul
multicent
doubleblind
placebocontrol
phase
ii
trial
prochym
osiri
therapeut
inc
columbia
md
patient
moder
sever
copd
primari
goal
trial
initi
may
determin
safeti
msc
infus
patient
lung
diseas
secondari
goal
initi
estim
potenti
efficaci
msc
decreas
chronic
inflamm
associ
copd
thu
improv
pulmonari
function
qualiti
life
trial
recruit
patient
six
particip
us
site
interim
data
analysi
infusion
toxic
signific
advers
event
report
notabl
signific
decreas
circul
inflammatori
marker
creactiv
protein
commonli
elev
patient
copd
note
treat
patient
trend
toward
improv
qualiti
life
indic
trial
end
fall
result
forthcom
lung
tissu
bioengin
one
rapidli
grow
area
investig
use
threedimension
matric
artifici
scaffold
growth
function
lung
tissu
stem
cell
ex
vivo
vivo
approach
increasingli
success
regener
tissu
includ
skin
vasculatur
cartilag
bone
recent
heart
liver
given
complex
architectur
structurefunct
relationship
lung
daunt
task
nonetheless
signific
progress
sever
area
notabl
msc
isol
amniot
fluid
umbil
cord
blood
bone
marrow
seed
biodegrad
polyglycol
acid
biosynthet
scaffold
also
onto
decellular
cadaver
scaffold
gener
tracheal
cartilag
use
repair
congenit
tracheal
defect
also
tendon
tissu
use
congenit
diaphragmat
defect
recent
culmin
success
clinic
use
bioengin
bronchu
extens
use
bioengin
trachea
bronchi
expect
threedimension
cultur
system
also
use
matric
ex
vivo
lung
parenchym
develop
studi
growth
factor
mechan
forc
lung
remodel
exampl
cultur
fetal
rat
lung
suspens
glycosaminoglycan
scaffold
result
format
alveolarlik
structur
scaffold
fetal
mous
cell
cultur
hydrogel
synthet
polym
scaffold
result
gener
alveolarlik
unit
stimul
fetal
mous
cell
polym
scaffold
differ
isoform
fibroblast
growth
factor
stimul
differ
pattern
develop
fetal
rat
lung
cell
cultur
biosynthet
gelatin
matrix
subsequ
inject
normal
rat
lung
induc
format
branch
saccul
epitheli
structur
reminisc
lung
parenchym
architectur
compar
scaffold
approach
use
studi
creation
pulmonari
vascular
network
investig
effect
vascular
endotheli
cell
develop
airway
alveolar
epitheli
tissu
studi
demonstr
power
cultur
system
evalu
lung
develop
repair
howev
mani
studi
design
demonstr
function
engin
lung
tissu
potenti
ventil
ga
exchang
also
clear
artifici
scaffold
provid
best
framework
gener
function
lung
tissu
artifici
scaffold
neither
fulli
replic
complex
lung
architectur
contain
matrix
compon
essenti
normal
lung
develop
function
recent
work
focus
use
natur
model
includ
nasal
septa
decellular
whole
lung
physiolog
scaffold
nativ
structur
lung
relev
extracellular
matrix
compon
includ
collagen
elastin
laminin
left
intact
remov
cellular
materi
deterg
agent
figur
particular
use
decellular
lung
grow
alveolar
cell
cultur
first
describ
year
ago
rediscov
test
vivo
applic
decellular
lung
mechan
ventil
undergo
vascular
perfus
provid
physiolog
studi
ex
vivo
lung
gener
two
recent
studi
demonstr
inocul
decellular
rat
lung
differ
mix
fetal
rat
lung
homogen
endotheli
cell
carcinoma
cell
result
recellular
decellular
scaffold
although
result
cellular
architectur
fulli
resembl
nativ
lung
recellular
lung
abl
surgic
implant
rat
previous
undergon
unilater
pneumonectomi
shortterm
surviv
rat
degre
ga
exchang
vascular
perfus
achiev
figur
import
proof
concept
studi
expect
stimul
number
compar
studi
util
decellular
lung
includ
human
lung
howev
studi
yet
evalu
whether
stem
progenitor
cell
isol
adult
bone
marrow
cord
blood
sourc
includ
lung
also
compar
form
airway
alveolarlik
structur
cultiv
matric
includ
decellular
whole
lung
scaffold
materi
whether
stem
progenitor
cell
cultur
fashion
use
function
lung
regener
vivo
popul
cell
describ
adult
lung
somat
progenitor
cell
isol
adult
sheep
lung
cultur
synthet
polym
construct
result
express
airway
alveolar
epitheli
marker
cell
structur
resembl
lung
airway
parenchyma
develop
impregn
construct
implant
subcutan
nude
mice
insert
wound
caviti
wedg
lung
resect
sheep
implant
adult
sheep
lung
mesenchym
stem
cell
cultur
synthet
fibronectinhydrogel
scaffold
lung
sheep
experiment
induc
emphysema
result
improv
tissu
mass
lung
perfus
howev
clear
whether
msc
differenti
paracrin
effect
model
adiposederiv
msc
cultur
ex
vivo
sheet
polyglycol
acid
appli
wound
edg
lung
volum
reduct
surgeri
rat
acceler
alveolar
vascular
regener
data
present
abstract
form
meet
also
at
meet
demonstr
intratrach
inocul
murin
msc
decellular
whole
mous
lung
result
growth
cell
along
airway
parenchym
lung
region
cell
demonstr
express
prospc
intratrach
inocul
decellular
rat
lung
murin
esc
result
appar
differenti
sever
epitheli
vascular
structur
lung
tissu
bioengin
stem
cell
project
area
intens
investig
addit
genet
regulatori
program
cultur
approach
includ
use
scaffold
mechan
forc
also
play
role
differenti
tissu
respond
gene
instruct
breath
lung
cell
subject
complex
mechan
load
includ
shear
due
air
movement
compress
due
pressur
stretch
due
expans
lung
tissu
inhal
utero
mechan
forc
part
gener
fetal
breathinglik
movement
produc
rhythmic
contract
respiratori
muscl
vari
frequenc
amplitud
normal
movement
essenti
develop
fetal
lung
differenti
aecii
cell
synthesi
surfact
protein
sever
vitro
studi
demonstr
applic
cyclic
mechan
stretch
cultur
mix
fetal
rodent
lung
cell
increas
spc
mrna
express
compar
cell
cultur
static
condit
influenc
stretch
induc
mechan
ventil
clinic
experiment
induc
lung
injuri
area
grow
investig
stretch
mechan
influenc
fluid
shear
intens
investig
influenc
develop
tissu
cartilag
bone
vascular
structur
msc
epc
well
esc
howev
studi
evalu
effect
physic
forc
develop
lung
epitheli
cell
develop
lung
structur
endogen
lung
progenitor
cell
either
embryon
adult
stem
cell
preliminari
data
present
meet
demonstr
cyclic
biaxial
mechan
stretch
msc
induc
gener
airway
alveolar
epitheli
protein
investig
effect
mechan
mechan
forc
develop
lung
stem
progenitor
cell
expect
area
intens
investig
obviou
challeng
develop
complex
function
lung
tissu
ex
vivo
recapitul
normal
dynam
integr
network
epitheli
cell
endotheli
cell
fibroblast
neuron
cell
inflammatori
cell
appropri
environ
architectur
correct
effector
molecul
mechan
forc
vital
proper
function
thorough
understand
synergist
interact
cell
physiolog
relev
condit
critic
develop
tissu
recapitul
structur
function
parent
tissu
vivo
use
bioreactor
system
may
provid
signific
inroad
area
thu
far
rel
limit
data
avail
model
lung
sever
recent
studi
demonstr
power
rotat
bioreactor
system
assess
interact
pathogen
bacteria
p
aeruginosa
lung
epitheli
cell
compar
growth
lung
epitheli
cell
dendrit
cell
macrophag
porou
filter
shown
mimic
innat
immun
pathway
lung
airway
recent
studi
demonstr
human
lung
cell
human
blood
capillari
abl
coat
onto
porou
polydimethylsiloxan
chip
mimick
alveoli
lung
lungonachip
devic
use
evalu
nanoparticl
bacteria
enter
lung
may
also
use
high
throughput
screen
drug
clearli
field
ripe
compar
technolog
advanc
bioengin
approach
lung
regener
figur
progress
use
embryon
stem
cell
lung
regener
repair
slower
develop
studi
past
approxim
year
sever
laboratori
demonstr
mous
human
esc
induc
cultur
acquir
phenotyp
marker
type
alveolar
epitheli
cell
includ
express
surfact
protein
lamellar
bodi
even
form
pseudoglandular
structur
howev
gener
occur
low
level
unless
esc
transduc
select
surfact
proteinexpress
cell
recent
protocol
manipul
cell
signal
pathway
guid
embryolog
lung
develop
develop
definit
endoderm
yield
robust
vitro
deriv
cell
phenotyp
characterist
aecii
cell
murin
esc
figur
deriv
airway
epitheli
cell
esc
proven
even
elus
although
develop
cell
phenotyp
marker
airway
epitheli
cell
demonstr
cultur
esc
airliquid
interfac
condit
recent
effect
matrix
protein
scaffold
mechan
forc
esc
differenti
lung
epithelium
investig
project
area
increas
investig
moreov
still
limit
avail
studi
effect
esc
administr
lung
vivo
endotrach
administr
mescderiv
aecii
cell
fetal
mice
result
surviv
cell
lung
mainten
prospc
express
period
howev
whether
cell
truli
engraft
function
signific
determin
recent
demonstr
intratrach
administr
aecii
cell
deriv
hesc
hesatii
cell
day
induct
acut
lung
injuri
result
intratrach
bleomycin
administr
immunocompromis
scid
mice
result
substanti
number
hesatii
cell
appear
engraft
lung
persist
spc
express
day
later
total
spcexpress
cell
appear
hesatii
origin
small
number
hesatii
cell
also
appear
differenti
type
cell
vivo
appar
engraft
observ
hesatii
cell
administ
uninjur
mice
control
monocyt
popul
administ
notabl
bleomycininduc
lung
injuri
significantli
reduc
mice
receiv
hesatii
cell
monocyt
vehicl
control
reduc
injuri
measur
qualit
quantit
measur
includ
importantli
function
measur
tidal
volum
arteri
oxygen
satur
first
publish
investig
demonstr
amelior
lung
injuri
esc
administr
notabl
studi
reflect
import
assess
function
physiolog
outcom
parallel
chang
lung
injuri
endpoint
histolog
inflamm
hydroxyprolin
content
whether
observ
amelior
lung
injuri
result
structur
engraft
administ
cell
reflect
previous
unsuspect
paracrin
effect
hesderiv
cell
yet
clear
nonetheless
result
number
ramif
includ
studi
potenti
use
esc
genet
lung
diseas
human
embryon
stem
cell
line
establish
cell
exhibit
normal
morpholog
protein
express
compar
he
cell
line
studi
detail
american
thorac
societi
issu
statement
call
expand
human
embryon
stem
cell
research
followup
statement
temporari
injunct
use
human
stem
cell
unit
state
hope
human
embryon
stem
cell
research
continu
expand
us
rapid
advanc
studi
esc
lung
injuri
repair
rapid
advanc
techniqu
gener
studi
induc
pluripot
stem
cell
rais
hope
cell
also
use
tool
gener
lung
epitheli
lung
cell
ex
vivo
excit
recent
advanc
gener
diseasespecif
humaninduc
pluripot
stem
cell
ip
cell
line
patient
genet
acquir
lung
diseas
includ
cystic
fibrosi
antitrypsin
diseas
sickl
cell
scleroderma
figur
howev
ip
cell
readili
differenti
cell
characterist
primit
endoderm
gener
cell
express
phenotyp
marker
lung
epitheli
cell
thu
far
prove
elus
also
strategi
yet
develop
ensur
cultur
extens
differenti
ip
esc
contain
remnant
undifferenti
tumorigen
cell
nonetheless
expect
rapid
advanc
field
occur
next
year
session
focus
recent
develop
character
organ
regul
regen
cell
adult
lung
steadi
state
lung
diseas
well
relationship
normal
endogen
lung
stem
cell
lung
cancer
stem
cell
paul
simmon
univers
texa
present
overview
model
stem
cell
organ
compar
contrast
function
properti
stem
progenitor
cell
hierarchi
rapidli
renew
tissu
complex
solid
organ
lung
tissu
mainten
repair
involv
coordin
interact
divers
cell
type
differ
prolif
differenti
potenti
point
although
stem
progenitor
cell
fate
organ
system
specifi
complex
interact
extracellular
matrix
protein
solubl
insolubl
factor
stromal
cell
element
compris
nich
organ
behavior
function
properti
may
conform
classic
stem
cell
model
discuss
fidel
lack
thereof
biomark
classifi
differ
cell
type
lung
exampl
although
lung
mesenchym
cell
character
express
antigen
resolv
lung
epitheli
cell
basi
differenti
express
work
laboratori
identifi
neg
lung
fibroblast
perivascular
cell
distal
lung
defin
express
pdgfa
receptor
susan
reynold
nation
jewish
health
denver
describ
experi
analyz
organ
tracheobronchi
stem
progenitor
cell
compart
normal
steadyst
naphthalen
treat
mice
studi
figur
schemat
protocol
use
differenti
esc
cell
phenotyp
characterist
type
alveolar
epitheli
cell
embryon
stem
cell
esc
effect
manipul
vitro
differenti
type
alveolar
epitheli
cell
use
lung
develop
cell
signal
pathway
guid
esc
differenti
fibroblast
growth
pro
spc
prosurfact
protein
c
adapt
permiss
refer
reveal
exist
three
relat
cytokeratin
po
tracheobronchi
epitheli
stemprogenitor
cell
differ
potenti
defin
differenti
express
cytokeratin
data
suggest
tracheobronchi
clara
ciliat
cell
lineag
maintain
unipot
cytokeratin
po
cell
steadi
state
multipot
cytokeratin
neg
po
po
cell
upregul
cytokeratin
naphthalenemedi
ablat
tracheobronchiolar
epitheli
cell
work
highlight
power
perturb
model
reveal
organ
regen
potenti
adult
lung
stem
progenitor
cell
recruit
repair
lung
injuri
ed
morrisey
univers
pennsylvania
spoke
critic
role
wnt
signal
pathway
lung
endoderm
progenitor
cell
fate
specif
develop
also
regul
maintain
integr
epitheli
mesenchym
cell
lineag
adult
lung
steadi
state
respons
injuri
diseas
particular
highlight
role
promot
regul
smooth
muscl
cell
differenti
transcript
activ
extracellular
matrix
protein
tenascin
c
turn
upregul
pdgfa
b
receptor
express
significantli
loss
result
defect
lung
vascular
airway
smooth
muscl
cell
develop
wherea
upregul
cpdgfr
signal
character
allergeninduc
asthma
mice
human
pulmonari
hypertens
present
follow
analyz
respons
bronchoalveolar
stem
progenitor
cell
pool
respons
injuri
insult
potenti
role
candid
lung
cancer
stem
cell
mutat
transform
barri
stripp
duke
univers
describ
studi
chimer
transgen
report
mous
model
combin
lineag
trace
clonal
analysi
halogen
thymidin
analog
label
prolifer
cell
measur
cycl
turnov
lung
stem
progenitor
cell
pool
steadi
state
naphthaleneinduc
airway
injuri
perturb
stem
cell
pool
size
differenti
potenti
manipul
canon
wnt
signal
studi
confirm
epitheli
stem
progenitor
cell
pool
maintain
integr
airway
epithelium
steadi
state
function
distinct
recruit
repair
lung
injuri
bronchiolar
epitheli
stem
cell
highest
regen
potenti
rel
quiescent
less
suscept
cytotox
insult
recruit
respons
sever
injuri
majd
moud
univers
pittsburgh
describ
analysi
behavior
candid
bronchioalveolar
stem
cell
basc
cours
elastas
cigarett
smokeinduc
emphysema
use
airway
lineag
tag
report
mous
model
preliminari
experi
show
increas
prolif
activ
basc
compart
injuri
togeth
augment
alveolar
type
cell
number
near
bronchioalveolar
duct
junction
consist
particip
basc
relat
precursor
alveolar
repair
although
promis
identifi
need
better
inform
anim
report
model
definit
biomark
delin
character
cell
particip
alveolar
repair
lung
diseas
kerstin
sinkeviciu
boston
children
hospit
share
data
analysi
cancer
propag
cell
lung
tumor
establish
orthotop
transplant
primari
adenocarcinoma
kra
mice
recapitul
key
featur
human
nonsmal
cell
lung
cancer
experi
compar
immunophenotyp
stain
pattern
candid
lung
canceriniti
propag
cell
normal
counterpart
test
hypothesi
share
common
cell
surfac
phenotyp
work
demonstr
fidel
orthotop
transplant
model
recapitul
properti
primari
lung
tumor
deriv
also
reveal
differ
genotyp
singl
locu
significantli
influenc
marker
repertoir
defin
cancer
propag
cell
differ
tumor
briefli
wherea
cancerpropag
cell
deriv
tumor
highli
enrich
po
cell
fraction
case
kra
tumor
po
neg
cell
equal
tumorigen
hand
analysi
neg
cell
abl
propag
tumor
egfr
mutant
tumor
although
studi
demonstr
signific
confound
factor
determin
natur
properti
aberr
cell
diseas
pathophysiolog
also
highlight
limit
phenotyp
analysi
absenc
robust
function
assay
assign
stem
panel
discuss
follow
rais
question
natur
properti
stem
cell
nich
lung
role
nich
specifi
stem
cell
fate
regul
regen
potenti
discuss
prerequisit
function
characterist
must
met
assign
stem
steadyst
perturb
injuri
also
debat
question
regen
repar
cell
differ
differ
context
concept
tempor
nich
also
rais
fact
properti
stem
cell
nich
alter
diseas
progress
pose
challeng
develop
strategi
har
potenti
endogen
regen
cell
deliv
exogen
repar
cell
consequ
repair
normal
nich
critic
consider
develop
success
stem
cellbas
stem
celldirect
therapi
lung
repair
summari
cell
lineag
trace
studi
interrog
gainoffunct
lossoffunct
tempor
analysi
lung
perturb
model
significantli
enhanc
understand
organ
regul
regen
cell
lung
howev
remain
press
need
identif
valid
biomark
biomark
repertoir
classifi
lung
stem
progenitor
cell
stromal
element
compris
nich
well
robust
function
assay
predict
regen
potenti
theme
session
focus
regen
potenti
lung
cell
lineag
tissu
variou
type
stem
cell
discuss
includ
esc
ip
cell
well
import
devis
provid
correct
function
nich
konrad
hochedling
harvard
stem
cell
institut
point
although
properti
esc
ip
similar
effici
reprogram
ip
low
key
bottleneck
field
actual
reprogram
individu
stem
cell
rare
event
viral
infect
ineffici
risk
insert
mutagenesi
reprogram
stochast
process
requir
sever
event
occur
correct
sequenc
furthermor
hochedling
point
differenti
cell
limit
replic
potenti
cultur
ultim
undergo
senesc
may
critic
barrier
scalabl
reprogram
addit
ip
cell
may
actual
deriv
adult
progenitor
cell
oppos
matur
cell
previous
assum
corollari
cellular
immort
may
therefor
elimin
key
roadblock
cellular
reprogram
thu
suggest
key
put
molecular
target
delet
inhibit
may
remov
major
roadblock
cellular
reprogram
darrel
kotton
boston
univers
focus
discuss
esc
ip
technolog
drive
differenti
endoderm
lung
epithelium
endoderm
point
caveat
ip
cell
still
mani
issu
work
includ
necess
multipl
integr
well
farfromneglig
potenti
oncogenesi
ip
cell
vivo
least
requir
integr
oncogen
myc
nevertheless
show
postnat
mous
fibroblast
induc
ip
phenotyp
use
lentivir
stem
cell
cassett
stemcca
express
cmyc
simultan
cell
valid
puripot
assay
includ
format
teratoma
vivo
well
chimera
deriv
mous
blastocyst
includ
deriv
lung
endoderm
shown
express
lung
epithelium
show
eleg
proof
principl
subsequ
cremedi
excis
stemcca
caus
revers
ip
phenotyp
previous
induc
stecca
express
take
lesson
endoderm
deriv
gastrul
driven
spatial
inform
impart
wnt
nodal
signal
among
factor
includ
fgf
show
lungspecif
endoderm
report
gene
express
driven
within
stecca
ipsderiv
endoderm
use
cocktail
fibroblast
growth
factor
fgf
nodal
carolyn
lutkzo
saban
research
institut
children
hospit
lo
angel
share
protocol
differenti
definit
endoderm
hesc
follow
development
principl
find
abl
sequenti
induc
express
mesoderm
definit
endoderm
primit
gut
tube
marker
includ
cours
cultur
hesc
use
sequenti
exposur
activin
activin
serum
kgf
serum
introduct
mix
induc
cytokeratin
spc
system
requir
optim
show
distinct
promis
feasibl
deriv
respiratori
endoderm
hesc
vitro
rick
wetsel
univers
texa
health
scienc
center
houston
describ
genet
strategi
use
spc
promoterdriven
neomycin
resist
cassettebas
select
system
drive
purif
deriv
hesc
greater
puriti
find
hescderiv
capabl
act
progenitor
also
amelior
bleomycininduc
lung
injuri
vivo
engraft
result
complet
rescu
lethal
mice
lastli
peter
lelk
drexel
univers
point
import
tissu
nich
direct
differenti
murin
esc
alveolarlik
construct
demonstr
exampl
organotyp
recombin
fetal
mous
lung
cell
within
matrigelcollagen
gel
furthermor
show
presenc
vascular
endotheli
vascular
structur
within
construct
indic
fgf
vegf
signal
well
shh
tenascin
play
import
role
process
demonstr
potenti
synthet
electrospun
collagen
matrix
versu
elastin
matrix
mimic
decellular
human
lung
extent
support
morphogenesi
fetal
lung
cellderiv
organotyp
epitheli
vascular
structur
taken
togeth
present
demonstr
signific
progress
deriv
definit
endoderm
well
respiratori
endoderm
mous
human
esc
also
potenti
deriv
cell
lineag
contribut
regen
medic
applic
lung
vivo
moreov
excit
gener
potenti
matrixdriven
tissu
engin
use
organotyp
recombin
stemprogenitor
cell
matrix
nevertheless
evid
much
remain
accomplish
particularli
term
scalabl
toxic
toler
connect
translat
undeni
excit
potenti
approach
human
diseas
applic
goal
session
review
progress
tissu
engin
encompass
biolog
scaffold
tissu
cultur
system
appli
lung
session
began
dame
julia
polak
imperi
colleg
london
videoconfer
provid
gener
overview
lung
tissu
engin
highlight
mani
challeng
current
face
field
yet
clear
progenitorcel
sourc
optim
gener
lung
tissu
candid
includ
primari
cell
adult
fetal
embryon
stem
cell
esc
adult
stem
cell
bone
marrow
cord
blood
circul
mesenchym
cell
nichespecif
cell
adiposederiv
cell
much
effort
current
spent
enhanc
lineagespecif
differenti
use
chemic
factor
factor
microenviron
success
drive
murin
esc
express
type
ii
pneumocyt
protein
eg
spc
via
direct
indirect
cocultur
method
earli
report
show
remov
retino
acid
cultur
increas
differenti
es
cell
process
long
day
yield
low
nevertheless
step
defin
factor
inhibit
stimul
differenti
process
use
pneumocyt
cell
extract
may
decreas
cultur
time
requir
increas
yield
wang
colleagu
show
use
gene
modul
transfect
spcpromoterneomycin
transgen
select
result
almost
pure
popul
cell
lamellar
bodi
spa
spb
spc
type
ii
pneumocyt
marker
recent
sever
laboratori
begun
studi
effort
engin
lung
tissu
ex
vivo
use
construct
materi
use
gener
construct
abl
stimul
cell
growth
differenti
cell
attach
deposit
extracellular
matrix
well
act
templat
tissu
vascular
growth
resorb
implant
insolubl
vitro
screen
toxic
studi
anoth
major
challeng
scale
expans
static
twodimension
cultur
mani
drawback
includ
lack
mix
control
option
requir
constant
feed
typic
result
low
yield
poor
qualiti
cell
contrast
advantag
cultur
simplic
applic
process
integr
autom
lead
enhanc
prolifer
thu
provid
higher
yield
shorter
time
cultiv
method
better
approxim
vivo
environ
cell
cell
cell
matrix
interact
use
bioreactor
permit
nutrient
penetr
integr
monitor
system
assess
viabil
specif
cell
need
algin
bead
brown
seawe
biocompat
fda
approv
use
cell
expans
bone
format
cell
encapsul
use
mass
product
embryoid
bodi
mainten
pluripot
human
es
cell
engin
bone
tissu
key
featur
stem
cell
bioprocess
control
reproduc
autom
valid
safeti
preclin
test
requir
anim
model
demonstr
safeti
engraft
efficaci
growth
control
immunocompat
demonstr
correct
defect
vivo
cell
construct
would
requir
clinic
qualiti
product
proceed
toward
clinic
applic
altern
possibl
cell
could
use
organsupport
devic
increas
effici
intervent
lung
assist
devic
multidisciplinari
approach
requir
engin
graft
replac
part
diseas
organ
recent
demonstr
macchiarini
denud
trachea
use
biolog
scaffold
onto
cultur
tracheal
epitheli
cell
cartilag
bone
marrow
stem
cell
seed
place
custom
bioreactor
engin
construct
cm
left
bronchu
replac
restor
normal
function
month
current
challeng
barrier
translat
stem
cell
therapi
lung
diseas
poor
understand
lineag
specif
differenti
low
function
differenti
cell
need
protocol
defin
reagent
ineffici
growth
cultur
issu
consid
product
develop
includ
cost
reimburs
industri
scale
product
transport
logist
storag
track
tissu
stem
cell
cultur
requir
reliabl
method
cell
expans
differenti
reduc
variabl
heterogen
increas
afford
reagent
regulatori
protocol
need
implement
address
donorassoci
risk
contamin
bioprocess
final
product
puriti
includ
genet
instabl
efficaci
safeti
surviv
vitro
regulatori
challeng
may
includ
decid
vivo
model
appropri
assess
cell
dose
microenviron
tumor
format
immunolog
issu
dr
polak
discuss
propos
approv
may
singl
european
unionwid
integr
tailor
regulatori
framework
advanc
therapi
pharmaceut
compani
industri
start
involv
cell
therapi
basic
question
need
address
whether
health
care
system
readi
incorpor
cellbas
therapi
lung
diseas
whether
limit
select
patient
session
end
conclus
stem
cell
therapi
lung
diseas
reach
matur
mani
challeng
yet
met
outlin
christin
finck
connecticut
children
medic
center
discuss
work
aim
use
stem
cell
treat
pulmonari
hypoplasia
preterm
infant
treatment
date
consist
mechan
ventil
surfact
therapi
inhal
extracorpor
membran
oxygen
ecmo
ecmo
vegf
administr
variabl
success
hypoplast
lung
reduc
lung
weight
fewer
gener
airway
result
fewer
alveoli
poor
epitheli
cell
differenti
surfact
defici
along
hypoplasia
correspond
pulmonari
arteri
henc
repres
ideal
environ
introduc
stem
cell
therapi
albeit
advantag
challeng
describ
dr
polak
dr
finck
summar
known
lung
deriv
definit
endoderm
attempt
devis
protocol
recapitul
critic
induct
event
earli
embryo
eg
wnt
tgfb
activina
use
induc
pluripot
cell
becom
definit
endoderm
comparison
seed
method
shown
esc
first
allow
becom
embryoid
bodi
eb
seed
onto
collagen
iv
coat
plate
cell
migrat
away
eb
express
wherea
cell
within
eb
retain
express
contrast
esc
plate
disaggreg
cell
collageniv
coat
plate
express
uniformli
ie
direct
differenti
direct
differenti
deriv
endoderm
finck
lab
develop
optim
protocol
esc
first
incub
media
contain
activina
day
singlecel
suspens
collageiv
coat
plate
similarli
shown
deriv
hepat
endoderm
importantli
lung
use
ngml
activin
ngml
import
migrat
epiblast
cell
though
primit
streak
embryogenesi
gave
rise
highest
number
cell
express
definit
endoderm
marker
lower
express
viscer
endoderm
marker
qrtpcr
increas
dose
activin
ngml
result
cell
greater
proport
cell
cell
express
ecadherin
cytokeratin
seen
immunofluoresc
stain
induct
optim
concentr
activin
step
protocol
involv
addit
import
pattern
foregut
endoderm
day
littl
ngml
cell
began
express
surfact
protein
b
c
well
clara
cell
secretori
protein
increas
ngml
result
increas
sp
decreas
express
pancreat
marker
condit
approxim
cell
express
spc
express
vimentin
ie
mesenchym
express
ie
endoderm
express
ectoderm
lamellar
bodi
format
also
demonstr
futur
work
determin
addit
enhanc
yield
preliminari
data
shown
use
protocol
context
collagen
matrigel
hydrogel
similar
result
work
develop
nonepitheli
tissu
lung
differenti
esc
hypox
condit
day
decreas
express
endoderm
marker
bri
increas
express
endotheli
marker
bind
vegf
day
vessellik
network
observ
well
increas
frequenc
pecam
cell
use
explant
model
pulmonari
damag
prematur
mous
lung
treat
receptor
block
vegf
result
hypoplast
lung
decreas
mean
cord
length
increas
frequenc
tunel
cell
undifferenti
differenti
endoderm
cell
ad
bottom
transwel
system
contain
hypoplast
lung
airliquid
interfac
compar
undifferenti
es
cell
differenti
endoderm
distal
airway
cell
promot
alveologenesi
increas
cord
length
frequenc
cell
decreas
tunel
cell
like
product
vegf
intratrach
deliveri
esderiv
distal
airway
cell
adult
mice
result
increas
level
vegf
brochoalveolar
lavag
bal
fluid
experi
relev
treatment
prematur
babi
utero
demonstr
cell
inject
tail
vein
dam
result
cell
migrat
lung
pup
futur
work
investig
deriv
pure
popul
differenti
cell
use
scaffold
treatment
prematur
mice
via
intratrach
tail
vein
intraamniot
inject
vascular
approach
tissueengin
lung
describ
david
hoganson
massachusett
gener
hospit
organ
shortag
critic
problem
transplant
lesson
learn
stemcel
biolog
tissu
engin
regen
medicin
may
abl
suppli
transplant
tissu
organ
replac
basic
level
success
engin
tissu
must
result
deliveri
oxygen
nutrient
cell
depend
surfac
area
concomit
remov
wast
co
organ
tissu
engin
must
match
surfac
area
volum
effect
mass
transfer
surfac
area
increas
r
volum
increas
r
challeng
vascular
tissu
engin
mimic
complex
microfluid
vasculatur
vari
depend
applic
exampl
make
fulli
develop
tissueengin
adult
lung
versu
neonat
lung
versu
ambulatori
lung
assist
devic
recapitul
basic
structur
alveolu
dr
hoganson
describ
concept
lung
assist
devic
would
compos
alveolar
chamber
separ
microvascular
network
channel
line
endotheli
cell
respiratori
membran
would
cover
pneumocyt
devic
would
bridg
transplant
endstag
lung
diseas
would
implant
upper
chest
blood
flow
pulmonari
arteri
return
left
atrium
oxygen
tube
would
hook
devic
skin
prototyp
multilay
surfac
area
cellular
devic
develop
vascular
alveolar
chamber
separ
silicon
respiratori
membran
highli
permeabl
co
anticoagul
sheep
blood
circul
devic
co
transfer
observ
increas
increas
rate
blood
flow
howev
extrapol
data
use
adult
lung
assist
devic
appear
layer
chamber
separ
siliconeco
membran
would
requir
surfac
area
flow
rate
mlmin
per
layer
would
remov
co
gener
rest
would
handl
lmin
blood
flow
approxim
cardiac
output
would
increas
po
blood
mm
hg
improv
design
need
mimic
high
densiti
capillari
system
maxim
network
minim
physiolog
shear
stress
otherwis
platelet
get
activ
obstruct
conduit
biomimet
design
princip
use
take
account
physiolog
vessel
diamet
length
parent
daughter
vessel
well
bifurc
angl
smoothli
round
apex
result
channel
aspect
ratio
smallest
channel
diamet
mm
micromachin
use
brass
mold
use
creat
exquisit
featur
ie
connect
dimens
vitro
test
anticoagul
sheep
blood
demonstr
atrial
pressur
vari
flow
rate
almost
ident
comput
fluid
dynam
analysi
achiev
physiolog
relev
biomimet
vascular
design
must
translat
biomimet
scaffold
materi
consist
collagenco
channel
diamet
mm
determin
ga
exchang
effici
occur
across
collagen
membran
transwel
creat
thin
collagen
film
respiratori
membran
pneumocyt
endotheli
cell
juxtapos
opposit
side
membran
transwel
attach
ga
exchang
fixtur
blood
allow
flow
endotheli
side
collagen
membran
flow
rate
mlmin
pneumocyt
side
expos
oxygen
flow
rate
mlmin
presenc
pneumocyt
endotheli
cell
result
increas
po
blood
mm
hg
cell
endotheli
cell
mm
hg
effect
seen
pco
use
cell
collagen
membran
cultur
day
presenc
pneumocyt
endotheli
cell
thick
collagen
film
decreas
approxim
mm
mm
incub
collagen
thick
decreas
mm
thu
begin
approxim
physiolog
measur
hope
collagen
would
digest
time
replac
natur
extracellular
matrix
although
studi
conduct
use
cell
line
human
endotheli
cell
success
seed
onto
collagen
membran
unknown
whether
special
endotheli
cell
requir
ed
ingenito
brigham
women
hospit
spoke
biolog
scaffold
stem
progenitor
cell
engraft
lung
emphysema
chosen
target
diseas
principl
learn
may
applic
structur
lung
diseas
one
must
understand
progenitor
cell
use
well
cell
repair
element
incorpor
scaffold
design
imped
match
mechan
consider
cell
attach
spread
cell
kinet
vivo
test
phenotyp
modul
could
accomplish
sever
way
includ
use
growth
factor
small
molecul
pharmacolog
modul
extracellular
matrix
epigenet
use
rnai
gene
therapi
genet
ovin
model
elastaseinduc
bullou
emphysema
autolog
adult
progenitor
cell
endobronchi
deliveri
select
cell
type
intraven
deliveri
facilit
cell
attach
spread
migrat
surviv
week
sitespecif
inject
cell
use
fibrinbas
engraft
scaffold
size
emphysemat
lesion
reduc
progenitor
cell
isol
biopsi
sheep
lung
demonstr
presenc
epitheli
cell
pancytokeratin
collagen
iv
fibrillin
mesenchym
cell
vimentin
collagen
iv
fibrillin
cultur
passag
mesenchym
lung
progenitor
mlpc
express
asma
vimentin
pdgfra
make
extracellular
matrix
protein
collagen
collagen
iv
adhes
glycoprotein
fibronectin
vitronectin
laminin
well
elastin
compon
tropoelastin
also
express
growth
factor
vegfa
import
lung
growth
develop
cell
doubl
time
hour
demonstr
stabl
genet
phenotyp
mlpc
express
integrin
av
integrin
character
defin
extracellular
matrix
ecm
attach
spread
pattern
import
cell
kinet
cell
phenotyp
need
taken
consider
design
scaffold
attach
ligand
maxim
attach
spread
barrier
attach
inject
cell
apoptos
strategi
promot
engraft
progenitor
prime
target
tissu
precondt
develop
engraft
system
modul
desir
effect
design
specif
precondit
focal
easi
control
result
cell
remov
biocompat
conduc
provision
matrix
deposit
variou
enzymat
system
test
tryspin
select
found
safe
simpl
control
stimul
cell
cycl
good
manufactur
practic
gmp
avail
inexpens
omiss
found
reduc
engraft
vivo
approach
use
deterg
thermal
shock
develop
sever
potenti
scaffold
compon
relev
properti
test
alon
combin
capac
promot
cell
attach
spread
vitro
differ
medium
condit
found
col
iv
fibronectin
polyllysin
pll
alon
promot
good
attach
mgml
howev
express
attach
ligand
vari
growth
condit
cell
cycl
phase
promot
spread
vitro
assay
combin
contain
mgml
fibronectin
col
col
iv
work
best
although
data
shown
compon
alon
work
almost
well
laminin
pll
alon
promot
spread
advers
affect
combin
spreadpromot
compon
ie
inhibit
format
focal
adhes
complex
integrin
attach
spread
vari
growth
cell
cycl
condit
also
mechan
consider
need
consid
scaffold
design
hydrogel
mechan
properti
differ
lung
tissu
caus
damag
prevent
engraft
exampl
algin
physic
hydrogel
support
cell
growth
rigid
brittl
wherea
fibrinogen
chemic
hydrogel
support
cell
growth
soft
elast
stressstrain
properti
similar
lung
low
physiolog
stress
substrat
also
influenc
abil
progenitor
cell
enter
cell
cycl
deliveri
also
affect
cell
survivalapoptosi
degrad
scaffold
implic
engraft
potenti
exampl
fibrinmedi
apoptosi
blunt
integrin
bind
vivo
test
role
site
condit
scaffold
composit
healthi
sheep
show
site
receiv
autolog
mlpc
graft
cell
segment
site
deliv
fibrinfibronectinpl
hydrogel
radiograph
evid
parenchym
inflamm
pleural
mediastin
patholog
week
treatment
lung
appear
grossli
normal
histolog
examin
inject
site
demonstr
cell
retent
defin
number
field
label
cell
substanti
greater
maintain
longer
graft
perform
hydrogel
scaffold
compar
graft
cell
aqueou
suspens
transplant
cell
shown
express
collagen
iv
week
inject
show
mainten
phenotyp
vivo
test
sheep
experiment
elastaseinduc
emphysema
show
treatment
mlpc
ffv
hydrogel
scaffold
associ
reduct
bulla
size
improv
perfus
compar
sham
treat
scaffold
alon
furthermor
mlpc
treatment
associ
retent
infus
cell
treatment
site
increas
tissu
cellular
increas
extracellular
matrix
increas
tissu
elastin
week
dr
ingenito
say
angiogen
respons
known
due
cell
infus
due
scaffold
also
state
lung
regener
reli
host
epitheli
cell
reepitheli
basement
membran
known
mesenchym
epitheli
transit
met
occur
system
futur
area
research
includ
role
mmp
adam
cell
migrat
prevent
apoptosi
role
matricellular
protein
tnc
preincub
strategi
augment
scaffold
bind
obviat
need
scaffold
viranuj
sueblinvong
emori
univers
present
work
lung
tissu
engin
msc
vitro
experi
induc
mechan
stretch
uniaxi
stretch
system
hz
elong
basal
medium
promot
cell
differenti
day
stretch
caus
signific
morpholog
chang
msc
day
induc
msc
prolifer
day
express
ccsp
cftr
mrna
surfac
protein
spc
express
induc
notabl
stretch
attenu
express
collagen
type
asmooth
muscl
action
sma
messeng
rna
use
small
airway
growth
medium
sagm
place
basal
medium
increas
level
ccsp
cftr
spc
mrna
cycl
protein
achiev
stretch
effect
synergist
small
airway
growth
media
sagm
also
augment
effect
stretch
reduc
collagen
type
asma
mrna
express
dr
sueblinvong
conclud
msc
excel
sourc
cell
ex
vivo
lung
tissu
regener
due
differenti
potenti
eas
suppli
furthermor
mechan
stretch
use
augment
lung
differenti
potenti
consider
must
given
composit
matrixscaffold
ecm
regul
lung
develop
repair
ecm
shown
regul
msc
differenti
vitro
msc
cultur
fibronectin
mgml
show
fibroblast
morpholog
increas
asma
aintegrin
receptor
cultur
laminin
mgml
import
appli
forc
promot
cell
growth
also
demonstr
report
clinic
transplant
tissueengin
airway
use
recipi
cell
seed
onto
donor
bronchi
futur
work
requir
understand
mechan
stretch
surfac
matric
affect
stem
cell
phenotyp
aquisit
receptor
enabl
interact
matrix
compon
mechanoreceptor
cftr
ion
channel
session
end
charl
vacanti
harvard
brigham
women
talk
use
adult
stem
cell
engin
new
pulmonari
tissu
two
main
compon
tissu
engin
cell
deliveri
system
scaffold
appropri
cell
type
limit
biolog
materi
decellular
lung
batchtobatch
variabl
contrast
hydrogel
provid
consist
biodegrad
result
good
distribut
cell
seed
revers
thermal
sensit
polym
pluron
liquid
room
temperatur
inject
vivo
form
gel
upon
reach
bodi
temperatur
use
gener
specif
shape
cell
suspend
gel
remain
viabl
implant
best
type
cell
use
engin
transplant
tissu
like
one
avoid
reject
therefor
adult
stem
cell
verysmallembryoniclik
vsel
cell
pluripot
stem
cell
good
candid
dr
vacanti
lab
describ
adult
stem
cell
name
sporelik
cell
ie
sub
popul
retain
embryoniclik
stem
cell
small
cell
less
micron
diamet
present
tissu
bodi
unknown
seed
bone
marrow
isol
tissu
initi
express
mani
embryon
stem
cell
marker
eg
induc
differenti
cell
three
germ
layer
appropri
cultur
condit
initi
sphere
format
begin
small
aggreg
cluster
driven
toward
particular
cell
type
cell
typic
prefer
revert
cell
type
tissu
isol
dr
vacanti
describ
sporelik
cell
lung
procur
predominantli
distal
lung
tissu
minc
expos
enzym
pass
mm
filter
follow
longdrawn
pasteur
pipett
nonadher
cell
form
aggreg
pneumospher
differenti
lung
cell
express
spc
cultur
serumcontain
medium
put
vivo
hydrogel
scaffold
appear
similar
distal
airway
tissu
cell
pattern
atyp
dr
vacanti
conclud
short
term
use
decellular
lung
may
better
scaffold
guid
pneumospher
pneumospher
also
driven
cell
type
cultur
appropri
condit
unclear
sporelik
cell
stem
cell
existfunct
vivo
cultur
phenomena
discuss
panel
consist
dr
jason
bate
uvm
peter
lelk
drexel
thoma
gilbert
pitt
overal
consensu
much
engin
enough
tissu
investig
reli
design
hope
cell
use
follow
design
principl
selforgan
littl
prod
direct
right
differenti
path
agre
use
matric
better
cultur
dish
normox
microenviron
typic
use
wrong
fact
embryon
environ
lung
develop
normoxia
hyperoxia
fetal
hemoglobin
conduct
oxygen
tissu
much
lower
oxygen
tension
postnat
discuss
move
question
research
question
phd
perspect
question
languag
cell
word
necessari
understand
rule
cell
behav
requir
interdisciplinari
field
math
comput
md
perspect
question
pulmonari
function
improv
patient
deterior
lung
function
ultim
may
need
cell
understand
factor
involv
develop
repair
perhap
administ
appropri
factor
extracellular
matrix
materi
may
suffic
discuss
evolv
question
whether
cell
smart
ie
know
provid
correct
environ
whether
one
realli
need
know
lung
engin
work
work
case
point
much
known
anesthesia
work
one
defin
endpoint
one
want
cell
function
express
certain
marker
mani
marker
session
end
express
continu
need
vitro
assay
system
well
vivo
function
assay
evalu
stemprogenitor
cell
may
possibl
use
intravit
microscopi
evalu
function
infus
cell
sinc
last
workshop
meet
advanc
made
use
vitro
model
translat
model
vivo
function
assay
goal
session
review
differ
studi
identifi
msc
interact
cell
innat
adapt
immun
system
sever
group
document
antiinflammatori
effect
exogen
administ
msc
anim
model
injuri
includ
lung
injuri
asthma
sepsi
discuss
session
preclin
data
therapeut
use
msc
human
promis
challeng
associ
explor
potenti
clinic
protocol
investig
safeti
efficaci
msc
therapi
lung
diseas
armand
keat
univers
toronto
present
key
issu
msc
studi
novel
type
bone
marrowderiv
progenitor
cell
role
immun
modul
studi
msc
tissu
regener
immunolog
progress
remark
rapid
pace
past
year
potenti
import
new
data
appear
weekli
scientif
literatur
littl
opportun
either
fulli
assess
contribut
adequ
evalu
direct
field
present
two
key
area
explor
first
attempt
provid
context
potenti
import
novel
progenitor
tissu
repair
role
signific
msc
mediat
immun
respons
studi
murin
human
msc
differ
sourc
discuss
well
popul
might
provid
insight
investig
tissu
repair
investig
msc
modul
immun
respons
place
context
evalu
basi
vitro
assay
preclin
model
use
sourc
cell
speci
differ
immun
cell
affect
key
issu
relev
futur
cell
therapi
lung
diseas
ryang
hwa
lee
texa
aandm
health
scienc
center
present
novel
work
demonstr
mice
intraven
administr
human
msc
hmsc
reduc
myocardi
infarct
damag
protect
effect
appar
paracrin
effect
secret
antiinflammatori
protein
msc
trap
lung
absenc
signific
engraft
furthermor
hmsc
lung
upregul
express
multipl
gene
larg
increas
antiinflammatori
protein
multifunct
protein
associ
inflamm
constitut
express
normal
adult
tissu
rapidli
induc
mani
differ
cell
type
inflammatori
mediat
tnfa
endotoxin
prostaglandin
pge
intraven
administr
hmsc
hmsc
transduc
small
interf
si
rna
decreas
inflammatori
respons
turn
reduc
infarct
size
improv
cardiac
function
similar
effect
reduc
inflammatori
respons
infarct
size
observ
iv
administr
recombin
result
suggest
improv
anim
model
patient
iv
infus
msc
least
part
explain
activ
msc
secret
conrad
lile
univers
torontounivers
health
network
mclaughlinrotman
centr
global
health
toronto
gener
hospit
present
work
use
msc
therapi
sepsi
sepsi
complic
includ
acut
lung
injuryacut
respiratori
distress
syndrom
multipl
organ
dysfunct
syndrom
import
caus
morbid
mortal
critic
ill
patient
despit
appropri
antimicrobi
therapi
previous
demonstr
administr
msc
amelior
experiment
lpsinduc
pulmonari
inflamm
ali
mice
howev
one
main
concern
regard
use
msc
patient
acut
lung
injuri
downregul
immun
respons
increas
possibl
sepsi
dr
lile
hypothes
administr
msc
would
also
reduc
sepsisassoci
inflamm
organ
injuri
clinic
relev
model
sepsi
investig
hypothesi
sepsi
induc
mice
cecal
ligat
punctur
clp
follow
intraven
inject
msc
salin
hour
later
msc
treatment
significantli
reduc
system
pulmonari
cytokin
kc
je
product
mice
clpinduc
sepsi
sepsisrel
acut
lung
injuri
organ
dysfunct
prevent
msc
treatment
addit
bacteri
clearanc
significantli
improv
msc
treatment
importantli
msc
treatment
significantli
reduc
mortal
septic
mice
receiv
appropri
antimicrobi
therapi
express
microarray
analysi
spleen
reveal
msc
therapi
affect
number
pathway
implic
sepsisrel
morbid
mortal
find
conjunct
result
report
studi
nemeth
colleagu
demonstr
feasibl
effect
msc
administr
experiment
sepsi
provid
basi
develop
potenti
effect
immunomodulatori
strategi
decreas
morbid
mortal
clinic
sepsi
michael
matthay
univers
california
san
francisco
present
stimul
work
use
msc
reduc
acut
lung
injuri
mice
ex
vivo
perfus
human
lung
matthay
research
group
use
vitro
vivo
ex
vivo
experiment
model
test
therapeut
valu
msc
treatment
ali
spirit
discuss
ensu
whether
msc
consid
treatment
acut
lung
injuri
accord
dr
matthay
evid
support
use
msc
found
grow
evid
suggest
profound
immunonodulatori
action
msc
lung
injuri
model
demonstr
efficaci
msc
ali
intratrach
deliveri
allogen
msc
use
improv
function
alveolar
epithelium
reduc
inflamm
improv
surviv
mous
model
ali
mice
injur
intratrach
endotoxin
mgkg
bone
marrowderiv
msc
cell
given
airspac
hour
endotoxin
reduc
sever
lung
injuri
measur
lung
protein
permeabl
pulmonari
edema
lung
histolog
therapeut
effect
associ
decreas
proinflammatori
cytokin
increas
antiinflammatori
cytokin
includ
surviv
also
improv
msc
treatment
recent
work
group
indic
msc
therapeut
valu
bacteri
pneumonia
mice
use
standard
model
escherichia
coli
pneumonia
mice
instil
bacteria
treat
msc
hour
instil
live
bacteria
bone
marrowderiv
msc
reduc
lung
injuri
improv
surviv
msc
treatment
associ
reduct
number
live
bacteria
lung
compar
salin
fibroblast
control
summari
result
msc
studi
mice
demonstr
treatment
msc
improv
surviv
reduc
lung
injuri
endotoxin
model
ali
consequ
downregul
proinflammatori
respons
increas
antiinflammatori
cytokin
time
msc
reduc
lung
injuri
improv
surviv
follow
live
e
coli
lung
injuri
associ
decreas
bacteri
count
relev
result
translat
observ
clinic
deriv
ex
vivo
lung
reperfus
model
use
perfus
albumin
physiolog
solut
plu
fresh
human
blood
human
lung
prepar
develop
studi
lung
fluid
balanc
clinic
relev
patholog
condit
administr
airspac
either
allogen
human
msc
medium
cultur
human
msc
revers
endotoxininduc
lung
injuri
measur
lung
water
lung
endotheli
permeabl
histolog
rate
alveolar
fluid
clearanc
base
sirna
knockdown
experi
benefici
effect
mediat
part
secret
keratinocyt
growth
factor
kgf
msc
reduc
lung
edema
normal
lung
endotheli
permeabl
restor
amilorid
sensit
sodium
fluid
transport
capac
injur
human
alveolar
epithelium
mechan
kgf
may
restor
alveolar
fluid
clearanc
includ
upregul
sodium
transport
enac
nakatpas
transcript
level
import
consider
develop
preclin
studi
determin
mechan
efficaci
safeti
use
msc
ali
also
necessari
determin
effici
rout
dose
time
deliveri
well
mani
msc
need
inocul
final
test
msccondit
medium
key
product
medium
kgf
recent
describ
import
consider
need
evalu
msc
use
human
cell
therapi
type
lung
diseas
daniel
j
weiss
univers
vermont
colleg
medicin
present
use
msc
immunomodul
allerg
airway
inflamm
work
base
previou
vitro
observ
msc
inhibit
prolifer
activ
wide
rang
immun
cell
notabl
lymphocyt
properti
serv
basi
recent
success
clinic
trial
autolog
allogen
mous
msc
immun
inflammatori
diseas
graft
versu
host
diseas
crohn
diseas
recent
chronic
obstruct
pulmonari
diseas
howev
mechan
msc
suppress
inflammatorybas
diseas
vivo
poorli
understood
clear
whether
effect
observ
vitro
parallel
occur
vivo
dr
weiss
reason
asthma
lymphocytemedi
diseas
might
amen
target
therapeut
msc
administr
might
also
provid
opportun
elucid
mechan
msc
action
vivo
group
found
system
administr
either
syngen
allogen
msc
antigen
sensit
mous
model
ovalbumininduc
allerg
airway
inflamm
inhibit
airway
hyperreact
well
eosinophil
lung
inflamm
ifngdepend
regulatori
cell
mechan
found
cmfda
cell
tracker
dyelabel
msc
migrat
mediastin
lymph
node
spleen
site
antigenspecif
lymphocyt
activ
model
contrari
exist
vitro
data
msc
administr
affect
antigenspecif
prolifer
rather
promot
phenotyp
vivo
increas
antigenspecif
immunoglobulin
serum
dr
weiss
colleagu
therefor
specul
mechan
msc
decreas
allerg
airway
inflamm
least
part
influenc
phenotyp
site
lymphocyt
activ
addit
direct
action
lung
addit
msc
administr
obviou
effect
gener
regulatori
cell
dr
weiss
conclud
system
msc
administr
antigensensit
inhibit
antigenspecif
cell
prolifer
interfer
antigen
present
dendrit
cell
effect
regulatori
cell
function
inhibit
prolifer
clonal
antigenspecif
cell
obviou
effect
cell
shift
cell
phenotyp
ifng
necessari
amelior
effect
msc
allerg
airway
inflamm
session
address
method
use
defin
endotheli
progenitor
popul
current
limit
approach
particip
discuss
contribut
specif
popul
endotheli
hematopoiet
endogen
lung
progenitor
cell
postnat
vasculogenesi
review
potenti
therapeut
applic
specif
cell
type
lung
diseas
includ
pah
ali
ard
session
began
mervin
yoder
indiana
univers
defin
differ
circul
popul
proangiogen
cell
discuss
approach
modul
abil
endotheli
coloni
form
cell
ecfc
gener
vascular
network
vivo
focus
modul
vessel
format
collagen
matric
began
overview
differ
type
circul
angiogen
cell
emphas
difficulti
identifi
true
epc
need
complementari
approach
establish
progenitor
potenti
whichev
popul
assess
given
specif
surfac
marker
identifi
true
epc
figur
circul
epc
typic
defin
adher
cell
captur
ingest
acetyl
lowdens
lipoprotein
acldl
bind
lectin
ulex
europaeu
day
vitro
cultur
defin
endotheli
cell
cultur
medium
howev
uptak
acldl
specif
endotheli
cell
distinguish
endotheli
cell
ec
progenitor
hematopoiet
cell
necessit
use
addit
properti
defin
specif
cell
type
adher
popul
mononuclear
cell
divid
earli
outgrowth
cell
also
known
cfuhil
late
outgrowth
cell
known
ecfc
depend
method
use
cultur
dr
yoder
review
evid
support
true
progenitor
role
popul
cell
describ
ecfc
ecfc
defin
function
abil
undergo
clonal
prolifer
replat
secondari
endotheli
coloni
form
tube
vitro
new
vessel
vivo
contain
within
ecfc
deriv
differ
sourc
vari
growth
potenti
cord
bloodderiv
ecfc
display
greater
prolif
potenti
ecfc
adult
peripher
blood
similarli
rat
pulmonari
microvascular
endotheli
cell
pmvec
display
higher
prolif
potenti
follow
serum
stimul
pulmonari
arteri
endotheli
cell
suggest
enrich
ecfc
vivo
transplant
experi
demonstr
ecfc
cultur
collagenfibronectin
gel
hour
implant
subcutan
nodscid
mice
demonstr
vessel
format
week
strong
stain
biophys
properti
gel
modul
collagen
concentr
turn
dictat
morpholog
ecfcderiv
structur
vivo
increas
matrix
collagen
concentr
result
increas
averag
total
vessel
area
dr
yoder
discuss
newer
strategi
isol
ecfc
cord
blood
base
surfac
phenotyp
suggest
modif
approach
flow
cytometri
could
allow
identif
popul
previous
detect
particular
biexponenti
display
may
facilit
detect
previous
undetect
popul
approach
use
character
cell
cord
blood
shown
highli
enrich
ecfc
popul
also
express
ecfc
form
blood
vessel
vivo
collagen
gel
women
breast
cancer
appear
mobil
live
ecfc
apoptot
circul
endotheli
cell
peripher
bloodstream
treatment
sunitinib
paclitaxel
second
part
talk
dr
yoder
discuss
role
cell
refer
circul
progenitor
cell
cpc
report
serv
biomark
cancer
progress
analysi
cpc
advanc
flow
cytometri
techniqu
demonstr
cell
variabl
express
abl
undergo
multilineag
engraft
nodscid
mice
unabl
give
rise
tubelik
structur
vitro
blood
vessel
nodscid
mice
vivo
tail
vein
inject
cpc
increas
melanoma
growth
women
breast
cancer
higher
ratio
proangiogen
nonangiogen
cpc
ratio
decreas
treatment
thu
cpc
enrich
hematopoet
stemprogenitor
activ
proangiogen
promot
tumor
growth
enrich
bloodstream
patient
breast
cancer
contrast
cell
describ
tumor
promot
cell
appear
vascular
progenitor
capabl
promot
vascular
growth
togeth
find
suggest
circul
cell
either
promot
vasculogenesi
actual
particip
vasculogenesi
former
like
hematopoiet
origin
wherea
latter
true
ecfc
suggest
deriv
endothelium
second
topic
session
address
contribut
bone
marrowderiv
precursor
tissueresid
endotheli
progenitor
vascular
remodel
pah
present
serpil
erzurum
cleveland
clinic
foundat
dr
erzurum
review
histopatholog
featur
pah
note
abnorm
indic
endotheli
injuri
dysfunct
includ
presenc
thrombot
lesion
plexogen
lesion
aneurysm
format
platelet
aggreg
fibrot
lesion
well
increas
endotheli
cell
prolifer
reflect
increas
stain
contrast
ecfc
describ
dr
yoder
cell
consider
bone
marrowderiv
cell
identifi
express
cell
normal
present
circul
low
level
give
rise
daughter
endotheliallik
cell
coloni
form
unit
endotheli
cell
cfuec
dr
erzurum
address
two
central
question
name
whether
bone
marrowderiv
epc
increas
circul
patient
pah
whether
number
relat
diseas
sever
remodel
fac
data
laboratori
demonstr
increas
progenitor
patient
idiopath
pulmonari
arteri
hypertens
ipah
correl
directli
increas
pulmonari
arteri
pressur
similar
work
studi
toshner
colleagu
demonstr
increas
cell
pah
increas
cell
pah
vascular
lesion
vivo
consist
dysfunct
endotheli
progenitor
pah
work
dr
erzurum
laboratori
also
show
increas
cfuec
deriv
circul
proangiogen
precursor
ipah
relat
percentag
cell
dr
erzurum
describ
role
isol
primari
lung
endotheli
cell
vessel
format
ipah
demonstr
increas
affin
cfuec
matur
endotheli
cell
tube
format
assay
follow
vivo
innocul
pah
cfuec
matrigel
plug
subcutan
nodscid
mice
increas
vessel
format
migrat
surround
tissu
dr
erzurum
describ
xenograft
model
human
endotheli
cell
isol
ipah
explant
lung
pah
cell
higher
engraft
control
increas
myelopoiesi
trend
higher
megakaryopoiei
increas
morbid
contrast
anim
inject
cell
unfavor
event
strikingli
infus
pah
cell
led
cardiac
lung
endotheli
injuri
situ
thrombosi
plasma
von
willebrand
factor
nitric
oxid
level
indic
endotheli
cell
activationinjuri
well
greater
vascular
network
format
lung
mice
engraft
pah
cell
find
suggest
associ
circul
human
progenitor
lung
vascular
remodel
pah
cell
foster
pulmonari
angiogen
remodel
nodscid
mice
associ
situ
thrombu
format
increas
von
willebrand
factor
suggest
endotheli
cell
injuri
platelet
activ
underli
mechan
dysfunct
proangiogen
cell
promot
vascular
injuri
remodel
pah
question
remain
answer
includ
determin
whether
proangiogen
cell
benefici
recoveri
vascular
injuri
contributori
remodel
chronic
determin
respons
underli
lung
health
select
type
epc
produc
bone
marrow
direct
function
lastli
benefit
therapi
inhibit
epc
regress
vascular
remodel
inflamm
asrar
malik
univers
illinoi
chicago
discuss
work
laboratori
deriv
mesoderm
cell
human
embryon
stem
es
cell
protect
effect
septic
shock
model
also
address
contribut
bone
marrowderiv
progenitor
cell
bmpc
regul
endotheli
barrier
function
mice
defin
microvascular
permeabl
alter
level
adheren
junction
hypothesi
underli
first
part
talk
coexpress
vascular
endotheli
growth
factor
receptor
vegfr
ace
defin
emerg
endotheli
vascular
lineag
differenti
human
embryon
stem
cell
studi
es
cell
differenti
embryoid
bodi
eb
suspens
cultur
fac
day
allow
identif
msc
kdr
ace
hsc
ace
kdr
epc
kdr
ace
subcultur
dissoci
eb
cell
day
reveal
morpholog
identifi
hematopoiet
coloni
also
epc
coloni
hematopoiet
cell
vecadherin
wherea
ace
kdr
cell
vecadherin
kdr
ace
cell
form
tubeslumen
matrigel
bd
bioscienc
bedford
transplant
studi
demonstr
improv
surviv
follow
lipopolysaccharid
lp
administr
hesderiv
eb
cell
kdr
ace
kdr
ace
wherea
advantag
transplant
hesderiv
adher
cell
condit
medium
eb
lung
level
greatest
lp
day
ebderiv
cell
second
part
talk
dr
malik
discuss
effect
bmpc
accumul
extravascular
lung
water
lp
bmpc
reduc
extravascular
lung
leak
lp
copd
known
cure
thu
current
therapeut
intervent
aim
provid
relief
symptom
oxygen
therapi
treatment
shown
improv
surviv
smoke
cessat
shown
slow
rate
fev
declin
copd
progress
gener
patient
treat
bronchodil
inhal
corticosteroid
measur
provid
signific
benefit
regard
diseas
progress
prognosi
characterist
biolog
activ
prochym
along
good
safeti
profil
human
trial
date
suggest
prochym
may
good
candid
address
unmet
medic
need
main
featur
pulmonari
emphysema
includ
rang
chronic
obstruct
pulmonari
diseas
copd
airflow
obstruct
result
destruct
alveolar
wall
distal
termin
bronchiol
without
signific
pulmonari
fibrosi
exist
clinic
approach
contribut
enlarg
amelior
emphysema
patient
life
qualiti
although
effect
cur
treatment
achiev
surgic
treatment
hand
involv
complex
procedur
specif
case
lung
transplant
lack
donor
consid
aspect
sever
experiment
model
propos
aim
increas
knowledg
pathophysiolog
process
enabl
new
clinic
approach
pulmonari
emphysema
cell
therapi
briefli
describ
use
cell
diseas
treatment
present
promis
therapeut
approach
great
potenti
applic
degen
pulmonari
diseas
way
intend
project
proposit
protocol
evalu
safeti
cell
therapi
pool
mononuclear
cell
bone
marrow
patient
clinic
laboratori
diagnosi
pulmonari
emphysema
advanc
stage
stage
iv
dyspnea
continu
appear
integr
progenitor
cell
suggest
leak
prevent
barrier
reanneal
futur
studi
direct
character
surfac
marker
mesoderm
deriv
precursor
lineag
trace
character
evalu
effect
growth
factor
signal
evalu
function
studi
vitro
vivo
bmpc
character
vecadherin
low
bmpc
express
lp
sens
taken
lung
day
postlp
challeng
bmpc
induc
activ
rhogtpas
endotheli
cell
involv
requir
paracrin
releas
suggest
cellular
crosstalk
basi
progenitor
cell
mediat
barrier
protect
judith
shizuru
univers
california
lo
angel
next
describ
approach
led
enrich
popul
lungderiv
cell
engraft
abl
gener
alveolar
endothelium
first
describ
strategi
tradit
use
isol
character
hematopoiet
stem
cell
hsc
base
abil
repopul
bone
marrow
lethal
irradi
mice
approach
adapt
isol
transplant
popul
mark
lung
cell
use
irradi
injuri
creat
nich
space
lung
obtain
candid
lungderiv
progenitor
cell
lung
juvenil
mice
wk
age
constitut
express
green
fluoresc
protein
gfp
dissoci
sort
distinct
popul
base
posit
select
surfac
marker
express
stem
cell
tissu
name
neg
select
marker
matur
lung
cell
eg
maclura
pomifera
lectin
mark
lung
subfract
intraven
cotranspl
togeth
nonlabel
purifi
hsc
lethal
irradi
adult
recipi
mice
whole
bone
marrow
use
control
five
fraction
sort
basi
surfac
express
lack
express
notch
popul
mark
exhibit
engraft
expans
gfp
cluster
recipi
lung
hour
postinfus
fraction
could
visual
lung
persist
day
greatest
frequenc
cell
obtain
young
mice
week
age
cluster
demonstr
morpholog
surfac
marker
express
capillari
endotheli
cell
show
increas
expans
week
compar
bone
marrowderiv
cell
popul
enrich
cell
express
marker
epc
kdr
thu
candid
lung
popul
cell
identifi
express
stem
cell
epc
surfac
marker
capabl
expans
engraft
cluster
contigu
cell
radiationinjur
recipi
lung
vivo
question
address
includ
whether
cell
cluster
clonal
whether
cell
contribut
meaning
repair
lung
injuri
whether
finit
amount
nich
space
cell
cell
resid
normal
lung
final
dynam
orchestr
regener
endotheli
epitheli
compon
addit
whether
cell
cluster
continu
capillari
need
determin
final
present
session
duncan
stewart
ottawa
health
research
institut
univers
ottawa
review
preclin
studi
assess
cellbas
therapi
pah
aliard
rational
administr
bone
marrowderiv
epc
base
evid
ec
apoptosi
initi
lesion
pah
subsequ
lead
degener
obliter
precapillari
arteriol
possibl
administr
epc
may
contribut
repair
regener
pulmonari
vessel
studi
culturederiv
epc
monocrotalin
mct
model
pah
demonstr
engraft
endotheliallik
cell
distal
precapillari
arteriol
week
postmct
prevent
develop
pulmonari
hypertens
day
cell
deliv
day
mct
delay
cell
therapi
week
postinjuri
still
effect
prevent
progress
deliveri
epc
genet
engin
overexpress
endotheli
nitric
oxid
synthas
eno
revers
establish
pah
base
preclin
find
earli
phase
clinic
trial
pulmonari
hypertens
cell
therapi
trial
phacet
studi
investig
gene
express
profil
normal
human
lung
tissu
lung
carcinoma
metastat
tumor
lung
express
gene
given
lung
tissu
sampl
examin
cdna
microarray
analysi
compar
normal
lung
tissu
addit
hope
identifi
particular
subset
lung
cancer
cell
enhanc
capac
prolifer
selfrenew
analog
stem
cell
recent
identifi
certain
type
leukemia
breast
cancer
brain
tumor
aim
studi
studi
blood
circul
level
bonemarrowderiv
progenitor
cell
epc
first
phase
epc
detect
healthi
nonsmok
volunt
valid
flow
cytometri
method
n
addit
epc
character
primari
cultur
analyz
epcspecif
marker
second
phase
epc
detect
peripher
blood
patient
chronic
obstruct
pulmonari
diseas
copd
patient
nonsmal
cell
lung
cancer
nsclc
primari
cultur
made
confirm
epc
isol
studi
perfum
safeti
phase
studi
patient
silicosi
treat
intrabronchi
instil
autolog
bone
marrow
deriv
mononuclear
cell
bmdmc
bronchoscopi
inclus
criteria
age
chronic
acceler
silicosi
character
fibrot
increas
last
two
year
fev
fvc
exclus
criteria
smoke
activ
tuberculosi
infect
cancer
autoimmun
disord
hematolog
hepat
cardiac
diseas
pregnanc
patient
subject
clinic
examin
answer
questionnair
qualiti
life
sgrq
dyspnea
score
borg
perform
high
resolut
ct
thorax
pulmonari
function
test
dl
co
test
lung
perfus
scintigraphi
day
treatment
initi
test
efficaci
safeti
eno
transfect
autolog
epc
patient
refractori
pah
studi
design
safeti
studi
patient
primari
endpoint
toler
cell
transplant
patient
pah
refractori
standard
therapi
autolog
earli
growth
epc
transfect
eno
deliv
swan
ganz
cathet
right
ventricl
dose
rang
studi
perform
day
cell
given
divid
dose
overlap
protocol
exclus
criteria
includ
hemodynam
instabl
hospit
worsen
right
heart
failur
previou
month
preliminari
data
thu
far
indic
trend
toward
lower
total
pulmonari
vascular
resist
day
intermedi
dose
seven
patient
need
complet
trial
anticip
time
line
month
complet
last
part
talk
focus
msc
therapi
ard
advantag
msc
includ
eas
growth
transfect
immunomodulatori
activ
potenti
use
allogen
cell
preclin
studi
perform
lp
model
mice
use
msc
msc
transduc
minut
administr
lp
dramat
improv
lung
histolog
releas
interferong
tnfa
similar
studi
undertaken
cecal
ligat
model
cell
administ
hour
surgeri
kill
hour
signific
reduct
circul
cytokin
improv
multiorgan
dysfunct
improv
surviv
suggest
msc
may
reprogram
monocytesmacrophag
increas
releas
prostaglandin
e
ali
ard
endotheli
activ
one
first
event
patholog
chain
lead
increas
airblood
permeabl
leukocyt
adhes
alveolar
fill
promis
result
safeti
efficaci
recent
publish
use
endotheli
precursor
cell
patient
primari
pulmonari
hypertens
recent
interim
result
current
trial
allogen
msc
copd
demonstr
safeti
suggest
efficaci
numer
recent
report
indic
msc
similar
cell
repair
injuri
lung
tissu
anim
model
activ
secret
therapeut
factor
without
longterm
engraft
cell
therefor
probabl
longterm
advers
effect
engraft
cell
greatli
decreas
therapeut
factor
identifi
administr
factor
may
provid
altern
strategi
therapi
lung
diseas
howev
msc
similar
cell
demonstr
remark
abil
engag
crosstalk
injur
tissu
produc
therapeut
benefit
secret
solubl
factor
celltocel
contact
may
duplic
administr
solubl
factor
therefor
optim
therapi
lung
diseas
may
involv
administr
solubl
factor
condit
cell
other
combin
still
condit
impress
data
recent
obtain
demonstr
msc
cell
alveolar
cell
condit
medium
cell
safe
effect
anim
model
lung
diseas
includ
acut
lung
injuri
asthma
copd
bronchopulmonari
dysplasia
other
recent
human
msc
demonstr
compar
effect
endotoxininjur
isol
human
lung
prepar
data
appear
provid
firm
basi
develop
clinic
trial
patient
rapid
progress
continu
made
number
creativ
approach
identifi
progenitor
stemlik
cell
lung
defin
hierarchi
differenti
cell
embryon
develop
respons
injuri
new
therapeut
strategi
like
aris
research
topic
may
identifi
factor
lung
diseas
enhanc
propag
differenti
stemlik
cell
result
anim
model
indic
cell
bone
marrow
sourc
engraft
differenti
multipl
type
cell
lung
howev
earli
report
mar
artifact
degre
engraft
usual
low
whether
specif
cell
bone
marrow
engraft
lung
well
understood
therefor
obviou
current
clinic
strategi
therapi
requir
longterm
engraft
lung
cell
bone
marrow
contrast
progress
recent
made
devis
artifici
lung
construct
may
provid
temporari
lung
assist
devic
patient
await
lung
transplant
much
left
ventricular
assist
devis
proven
use
patient
await
cardiac
transplant
parallel
rapid
progress
made
devis
ex
vivo
threedimension
cultur
system
gener
function
lung
tissu
might
conceiv
implant
diseas
lung
reconstruct
damag
structur
lung
patient
chronic
lung
diseas
remain
specif
still
distant
goal
current
clinic
research
clinic
trial
cell
therapi
lung
diseas
lag
behind
similar
therapi
diseas
part
diseas
present
difficult
diseas
target
howev
repres
sever
patient
orient
respiratori
diseas
foundat
ask
allow
perfect
becom
enemi
good
conprecaut
clinic
trial
cell
relat
therapi
lung
diseas
must
proceed
keen
awar
everi
known
therapeut
measur
patient
potenti
produc
advers
effect
trial
new
therapi
must
therefor
base
care
evalu
potenti
benefit
potenti
risk
patient
far
discern
among
potenti
advers
effect
cell
therapi
current
consider
creation
tumor
malign
patient
risk
present
cell
type
propag
cultur
howev
risk
vari
greatli
biolog
properti
cell
condit
cultur
basi
evid
clear
differ
probabl
risk
administr
cell
like
human
msc
similar
cell
regularli
undergo
senesc
expand
associ
administr
immort
cell
like
es
ip
cell
undergo
senesc
cultur
cell
therapi
probabl
pose
risk
still
undefin
among
potenti
risk
intraven
infus
mani
cell
trap
lung
therefor
pose
risk
lethal
pulmonari
emboli
cell
repair
tissu
may
enhanc
growth
undetect
cancer
demonstr
msc
anim
model
local
administr
bolu
cell
may
prompt
cell
aggreg
differenti
bone
inappropri
structur
definiton
abbrevi
copd
chronic
obstruct
pulmonari
diseas
es
ip
msc
mesenchym
stem
cell
subsequ
discuss
pro
con
move
toward
clinic
trial
led
dr
zea
borok
univers
southern
california
kenneth
brigham
emori
univers
polli
parson
univers
vermont
stephen
rennard
univers
nebraska
steven
shapiro
univers
pittsburgh
current
two
activ
clinic
trial
stemprogenitor
cell
lung
diseas
one
pulmonari
hypertens
copd
also
one
clinic
investig
progenitor
cell
lung
cancer
occur
unit
state
canada
list
clinicaltrialsgov
tabl
discuss
began
question
whether
singl
cell
type
answer
lung
regener
discuss
regard
cell
type
best
may
differ
differ
diseas
suggest
perhap
multipl
cell
type
orchestr
approach
need
question
rais
whether
readi
clinic
trial
consider
discuss
focus
need
empiric
clinic
medicin
felt
field
whole
advanc
initi
discuss
year
ago
regard
whether
cell
engraft
evalu
effect
cellbas
therapi
includ
immun
effect
felt
panel
member
overal
need
proceed
human
studi
anim
studi
insuffici
strong
sentiment
regard
need
good
databas
sampletissu
bank
gener
much
inform
possibl
ongo
clinic
trial
felt
registri
establish
includ
small
trial
trial
store
blood
sampl
later
analysi
concern
mani
commerci
run
trial
collect
suffici
sampl
patient
inform
make
data
publicli
avail
final
discuss
focus
ultim
goal
cellbas
therapi
alter
structur
lung
need
good
functionalphysiolog
correl
uniform
agreement
best
endpoint
evalu
structur
session
end
recognit
sinc
clinic
trial
start
major
need
defin
mechanist
clinic
endpoint
learn
much
ongo
trial
overal
consensu
lung
diseas
still
present
major
challeng
increas
although
uniform
support
cautious
move
ahead
addit
care
design
trial
investig
shift
previou
confer
salient
point
procon
discuss
summar
tabl
session
includ
present
dian
kraus
yale
current
statu
potenti
engraft
bone
marrowderiv
cell
lung
epithelium
concept
remain
controversi
although
sever
paper
suggest
lessexplor
lessunderstood
bone
marrowderiv
cell
popul
may
inde
engraft
although
still
low
level
airway
alveolar
epithelium
subsequ
present
jeffrey
kahn
univers
minnesota
consid
ethic
polici
issu
regard
use
stem
cell
move
toward
clinic
trial
cell
therapi
investig
lung
diseas
follow
jame
kiley
phd
chief
lung
biolog
diseas
branch
nhlbi
present
nhlbi
perspect
stem
cell
cell
therapi
approach
lung
diseas
avail
resourc
nhlbi
nih
describ
includ
nih
product
assist
cellular
therapi
pact
program
http
wwwpactgroup
net
addit
resourc
list
confer
recommend
also
includ
session
present
daniel
rose
md
john
walsh
md
univers
florida
ami
farber
phd
ceo
respect
pulmonari
fibrosi
foundat
alpha
one
foundat
lam
treatment
allianc
import
stem
cell
research
particular
patient
popul
role
nonprofit
research
organ
support
novel
area
research
zea
borok
md
univers
southern
california
gave
compar
present
behalf
american
thorac
societi
continu
accumul
data
anim
model
clinic
trial
suggest
cellbas
therapi
novel
bioengin
approach
may
potenti
therapeut
strategi
lung
repair
remodel
injuri
parallel
understand
role
endogen
lung
progenitor
cell
provid
insight
mechan
lung
develop
repair
injuri
may
also
provid
novel
therapeut
strategi
remark
progress
made
area
sinc
last
confer
year
ago
hope
workshop
recommend
tabl
spark
new
research
provid
understand
mechan
repair
lung
injuri
sound
scientif
basi
therapeut
use
stem
cell
therapi
lung
diseas
author
disclosur
djw
consult
glaxosmithklin
advisori
board
ala
receiv
clinic
trial
support
osiri
therapeut
inc
ib
own
patent
australian
stem
cell
centr
zb
ck
apm
sr
mr
financi
relationship
commerci
entiti
interest
subject
manuscript
bs
receiv
lectur
fee
astrazeneca
dw
djp
financi
relationship
commerci
entiti
interest
confer
